[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Nevada	27-1275784
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification Number)

~~802 N. Douty~~106 K Street, Suite 300
~~Hanford,~~Sacramento, California ~~93230~~95814
(Address of Principal Executive Offices, including Zip Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file reports), and (2) has been subject to such filing requirements for the past 90 days. x YES ¨ NO

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES x NO ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ¨ NO x

As of ~~May 10, 2017, 17,979,681~~February 8, 2018, 24,336,913 shares of the registrant's common stock were outstanding.

This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The statements contained in this Quarterly Report on Form 10-Q that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), ~~and~~which are subject to the "safe harbor" created by those sections. ~~All statements other than statements of historical fact are statements that could be deemed~~These forward-looking statements ~~including~~include but are not limited to, any statements concerning projections of revenue, margins, expenses, tax provisions, earnings, cash flows and other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements regarding our ability to raise capital in the future; any statements concerning expected development, performance or market acceptance relating to our products or services or our ability to expand our grower or customer bases or to diversify our product offerings; any statements regarding future economic conditions or performance; any statements of expectation or belief; any statements regarding our ability to retain key employees; and any statements of assumptions underlying any of the foregoing. These forward-looking statements are often identified by the use of words such as, but not limited to, "anticipate," "believe," "can," "continue," "could," "designed," "estimate," "expect," "intend," "may," ~~"will,~~"plan," ~~"plan,~~"potential," "project," "seek," "should," "target," "will," "would," and similar expressions or variations intended to identify forward-looking ~~statements.~~statements, although not all forward-looking statements contain these identifying words. We have based these forward-looking statements on our current expectations about future events. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Risks, uncertainties and assumptions include the following:

You are urged to carefully review the disclosures made concerning risks and uncertainties that may affect our business or operating results, which include, among others, those listed in Part I, Item 1A. "Risk Factors" of our Annual Report on Form 10-K, ~~for~~which was filed with the ~~fiscal year ended June 30, 2016.~~SEC on September 20, 2017.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Many factors discussed in this Quarterly Report on Form 10-Q, some of which are beyond our control, will be important in determining our future performance. Consequently, these statements are inherently uncertain and actual results may differ materially from those that might be anticipated from the forward-looking statements. In light of these and other uncertainties, you should not regard the inclusion of a forward-looking statement in this Quarterly Report on Form 10-Q as a representation by us that our plans and objectives will be achieved, and you should not place undue reliance on such forward-looking statements. All forward-looking statements included herein are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Furthermore, such forward-looking statements represent our views as of, and speak only as of, the date of this ~~Report.~~Quarterly Report on Form 10-Q, and such statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. We undertake no obligation to publicly update any forward-looking statements, or to update the reasons why actual results could differ materially from those anticipated in any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

When used in this Quarterly Report on Form 10-Q, the terms "we," "us," "our," "the Company," "S&W" and "S&W Seed" refer to S&W Seed Company and its subsidiaries or, as the context may require, S&W Seed Company only. Our fiscal year ends on June 30, and accordingly, the terms "fiscal ~~2017,~~2018," "fiscal ~~2016"~~2017" and "fiscal ~~2015"~~2016" in this Quarterly Report on Form 10-Q refer to the respective fiscal ~~years~~year ended June 30, 2018, 2017 ~~2016~~ and ~~2015,~~2016, respectively, with corresponding meanings to any fiscal year reference beyond such dates. Trademarks, service marks and trade names of other companies appearing in this report are the property of their respective holders.

		March 31,		June 30,		December 31,		June 30,
		2017		2016		2017		2017
ASSETS

CURRENT ASSETS
Cash and cash equivalents	$	3,320,659	$	6,904,500	$	5,454,694	$	745,001
Accounts receivable, net		23,179,172		27,619,599		25,250,475		23,239,325
Inventories, net		38,052,248		21,846,130		70,486,985		31,489,945
Prepaid expenses and other current assets		1,560,194		1,218,280		1,500,066		1,249,921
TOTAL CURRENT ASSETS		66,112,273		57,588,509		102,692,220		56,724,192

Property, plant and equipment, net		13,465,805		12,600,106		13,630,123		13,581,576
Intangibles, net		35,456,992		37,006,802		33,810,687		34,939,079
Goodwill		10,292,265		10,292,265		10,292,265		10,292,265
Deferred tax assets		7,728,370		7,279,923
Other assets		1,553,503		2,237,380		1,568,286		1,563,176
TOTAL ASSETS	$	134,609,208	$	127,004,985	$	161,993,581	$	117,100,288

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
Accounts payable	$	7,218,726	$	14,303,877	$	32,831,640	$	7,157,745
Accounts payable - related parties		77,599		396,027		117,164		331,694
Deferred revenue		570,662		509,857		55,442		880,326
Accrued expenses and other current liabilities		1,590,559		2,385,160		2,671,495		2,733,718
Lines of credit		36,166,497		16,687,473
Lines of credit, net						27,592,603		27,399,784
Current portion of contingent consideration obligation		2,346,091		-		-		2,500,000
Current portion of long-term debt		10,261,411		275,094
Current portion of convertible debt, net		-		6,840,608
Current portion of long-term debt, net						358,864		10,309,664
TOTAL CURRENT LIABILITIES		58,231,545		41,398,096		63,627,208		51,312,931

Contingent consideration obligation		-		2,268,416
Long-term debt, less current portion		1,040,414		11,114,333
Long-term debt, net, less current portion						13,203,191		1,096,155
Derivative warrant liabilities		3,512,700		4,354,100		-		2,836,600
Other non-current liabilities		42,049		108,596		781,629		632,947

TOTAL LIABILITIES		62,826,708		59,243,541		77,612,028		55,878,633

STOCKHOLDERS' EQUITY
Preferred stock, $0.001 par value; 5,000,000 shares authorized;
no shares issued and outstanding		-		-		-		-
Common stock, $0.001 par value; 50,000,000 shares authorized;
17,989,167 issued and 17,964,167 outstanding at March 31, 2017;
17,086,111 issued and 17,061,111 outstanding at June 30, 2016;		17,989		17,086
24,353,300 issued and 24,328,300 outstanding at December 31, 2017;
18,004,681 issued and 17,979,681 outstanding at June 30, 2017;						24,353		18,004
Treasury stock, at cost, 25,000 shares		(134,196)		(134,196)		(134,196)		(134,196)
Additional paid-in capital		82,822,874		78,282,461		108,568,030		83,312,518
Accumulated deficit		(5,345,205)		(4,614,244)		(18,653,679)		(16,436,286)
Accumulated other comprehensive loss		(5,578,962)		(5,789,663)		(5,422,955)		(5,538,385)
TOTAL STOCKHOLDERS' EQUITY		71,782,500		67,761,444		84,381,553		61,221,655
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	134,609,208	$	127,004,985	$	161,993,581	$	117,100,288

		Three Months Ended				Nine Months Ended
		March 31,				March 31,				Three Months Ended				Six Months Ended
		2017		2016		2017		2016		December 31,				December 31,
										2017		2016		2017		2016
Revenue	$	21,012,243	$	25,013,779	$	57,487,560	$	61,409,948	$	20,532,796	$	24,225,744	$	31,244,512	$	36,475,317

Cost of revenue		15,208,896		19,500,605		44,520,476		49,890,460		15,860,629		19,005,270		24,236,757		29,311,580

Gross profit		5,803,347		5,513,174		12,967,084		11,519,488		4,672,167		5,220,474		7,007,755		7,163,737

Operating expenses
Selling, general and administrative expenses		2,720,131		2,459,737		7,767,530		7,239,821		2,446,955		2,592,059		5,361,035		5,047,263
Research and development expenses		714,512		626,316		2,204,625		2,049,332		855,164		748,571		1,597,081		1,490,113
Depreciation and amortization		798,559		796,062		2,475,710		2,376,101		870,981		842,454		1,759,233		1,677,151
Disposal of property, plant and equipment loss (gain)		7,766		(2,427)		7,630		(2,427)
Impairment charges		319,001		-		319,001		-
Disposal of property, plant and equipment gain										(15,413)		-		(81,776)		-

Total operating expenses		4,559,969		3,879,688		12,774,496		11,662,827		4,157,687		4,183,084		8,635,573		8,214,527

Income (loss) from operations		1,243,378		1,633,486		192,588		(143,339)		514,480		1,037,390		(1,627,818)		(1,050,790)

Other expense
Foreign currency loss (gain)		2,125		87,342		(4,358)		(164,471)		7,472		(2,837)		22,030		(6,483)
Change in derivative warrant liabilities		(1,009,901)		(694,800)		(841,400)		(2,176,800)		341,199		(959,200)		(431,300)		168,500
Change in contingent consideration obligations		(86,688)		48,963		77,675		1,490		-		57,282		-		164,363
Loss on equity method investment		95,591		28,916		144,841		252,619		-		-		-		49,249
Gain on sale of marketable securities		-		-		-		(123,038)
Interest expense - amortization of debt discount		150,875		1,150,412		1,131,994		3,111,866		33,100		381,660		67,099		981,118
Interest expense - convertible debt and other		300,627		438,879		948,211		1,672,863		383,894		295,042		731,623		647,584

Income (loss) before income taxes		1,790,749		573,774		(1,264,375)		(2,717,868)		(251,185)		1,265,443		(2,017,270)		(3,055,121)
Provision (benefit) from income taxes		463,509		5,901		(533,414)		(2,773,294)
Provision (benefit) for income taxes										148,702		106,485		200,123		(996,923)
Net income (loss)	$	1,327,240	$	567,873	$	(730,961)	$	55,426	$	(399,887)	$	1,158,958	$	(2,217,393)	$	(2,058,198)

Net income (loss) per common share:
Basic	$	0.07	$	0.04	$	(0.04)	$	0.00	$	(0.02)	$	0.07	$	(0.11)	$	(0.12)
Diluted	$	0.02	$	0.04	$	(0.09)	$	0.00	$	(0.02)	$	0.01	$	(0.11)	$	(0.12)

Weighted average number of common shares outstanding:
Basic		17,963,598		15,420,308		17,630,906		14,278,107		21,130,960		17,821,547		20,643,973		17,467,370
Diluted		17,979,177		15,420,308		17,718,243		14,278,107		21,130,960		17,996,221		20,643,973		17,467,370

		Three Months Ended				Nine Months Ended				Three Months Ended				Six Months Ended
		March 31,				March 31,				December 31,				December 31,
		2017		2016		2017		2016		2017		2016		2017		2016

Net income (loss)	$	1,327,240	$	567,873	$	(730,961)	$	55,426	$	(399,887)	$	1,158,958	$	(2,217,393)	$	(2,058,198)

Foreign currency translation adjustment, net of income taxes		454,319		383,723		210,701		(457,391)		(41,223)		(448,784)		115,430		(243,621)

Comprehensive income (loss)	$	1,781,559	$	951,596	$	(520,260)	$	(401,965)	$	(441,110)	$	710,174	$	(2,101,963)	$	(2,301,819)

	��	Common Stock			Treasury Stock				Additional Paid-In		Accumulated		Accumulated Other Comprehensive		Total Stockholders'	Common Stock			Treasury Stock				Additional Paid-In		Accumulated		Accumulated Other Comprehensive		Total Stockholders'
		Shares		Amount	Shares		Amount		Capital		Deficit		Loss		Equity	Shares		Amount	Shares		Amount		Capital		Deficit		Loss		Equity

Balance, June 30, 2015		13,479,101	$	13,479	(25,000)	$	(134,196)	$	62,072,379	$	(4,979,471)	$	(5,096,586)	$	51,875,605

Stock-based compensation - options, restricted stock, and RSUs		-		-	-		-		917,487		-		-		917,487
Beneficial conversion feature		-		-	-		-		871,862		-		-		871,862
Net issuance to settle RSUs		45,410		45	-		-		(83,848)		-		-		(83,803)
Proceeds from sale of common stock, net of fees and expenses		3,306,404		3,306	-		-		13,306,410		-		-		13,309,716
Exercise of stock options, net of withholding taxes		8,751		9	-		-		34,557		-		-		34,566
Other comprehensive loss		-		-	-		-		-		-		(457,391)		(457,391)
Net income		-		-	-		-		-		55,426		-		55,426
Balance, March 31, 2016		16,839,666	$	16,839	(25,000)	$	(134,196)	$	77,118,847	$	(4,924,045)	$	(5,553,977)	$	66,523,468

Balance, June 30, 2016		17,086,111	$	17,086	(25,000)	$	(134,196)	$	78,282,461	$	(4,614,244)	$	(5,789,663)	$	67,761,444	17,086,111	$	17,086	(25,000)	$	(134,196)	$	78,282,461	$	(4,614,244)	$	(5,789,663)	$	67,761,444

Stock-based compensation - options, restricted stock, and RSUs		-		-	-		-		885,456		-		-		885,456	-		-	-		-		578,659		-		-		578,659
Net issuance to settle RSUs		56,954		57	-		-		(107,552)		-		-		(107,495)	41,270		41	-		-		(75,124)		-		-		(75,083)
Issuance of common stock upon conversion of principal and interest of convertible debentures		684,321		684	-		-		3,160,588		-		-		3,161,272
Issuance of common stock upon conversion of principal and
interest of convertible debentures																684,321		684	-		-		3,160,589		-		-		3,161,273
Exercise of stock options, net of withholding taxes		161,781		162	-		-		601,921		-		-		602,083	161,781		162	-		-		601,921		-		-		602,083
Other comprehensive loss																-		-	-		-		-		-		(243,621)		(243,621)
Net loss																-		-	-		-		-		(2,058,198)		-		(2,058,198)
Balance, December 31, 2016																17,973,483	$	17,973	(25,000)	$	(134,196)	$	82,548,506	$	(6,672,442)	$	(6,033,284)	$	69,726,557

Balance, June 30, 2017																18,004,681	$	18,004	(25,000)	$	(134,196)	$	83,312,518	$	(16,436,286)	$	(5,538,385)	$	61,221,655

Stock-based compensation - options, restricted stock, and RSUs																-		-	-		-		451,033		-		-		451,033
Net issuance to settle RSUs																88,619		89	-		-		(113,777)		-		-		(113,688)
Proceeds from sale of common stock, net of fees and expenses																6,260,000		6,260	-		-		22,512,956		-		-		22,519,216
Reclassification of warrants upon expiration of repricing provisions																-		-	-		-		2,405,300		-		-		2,405,300
Other comprehensive income		-		-	-		-		-		-		210,701		210,701	-		-	-		-		-		-		115,430		115,430
Net loss		-		-	-		-		-		(730,961)		-		(730,961)	-		-	-		-		-		(2,217,393)		-		(2,217,393)
Balance, March 31, 2017		17,989,167	$	17,989	(25,000)	$	(134,196)	$	82,822,874	$	(5,345,205)	$	(5,578,962)	$	71,782,500
Balance, December 31, 2017																24,353,300	$	24,353	(25,000)	$	(134,196)	$	108,568,030	$	(18,653,679)	$	(5,422,955)	$	84,381,553

		Nine Months Ended				Six Months Ended
		March 31,				December 31,
		2017		2016		2017		2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net (loss) income	$	(730,961)	$	55,426
Adjustments to reconcile net (loss) income to net cash used in operating activities
Net loss					$	(2,217,393)	$	(2,058,198)
Adjustments to reconcile net loss from operating activities to net cash used in operating activities
Stock-based compensation		885,456		917,487		451,033		578,659
Change in allowance for doubtful accounts		99,640		(7,350)
Bad debt expense						20,547		-
Depreciation and amortization		2,475,710		2,376,101		1,759,233		1,677,151
Loss (gain) on disposal of property, plant and equipment		7,630		(2,427)
Impairment charges		319,001		-
Gain on disposal of property, plant and equipment						(81,776)		-
Change in deferred tax asset		(448,447)		(2,974,375)		-		(1,034,439)
Change in foreign exchange contracts		50,522		(55,817)		100,864		234,286
Change in derivative warrant liabilities		(841,400)		(2,176,800)		(431,300)		168,500
Change in contingent consideration obligations		77,675		1,490
Change in contingent consideration obligation						-		164,363
Amortization of debt discount		1,131,994		3,111,866		67,099		981,118
Gain on sale of marketable securities		-		(123,038)
Intercompany foreign exchange gain		-		(284,774)
Loss on equity method investment		144,841		252,619		-		49,249
Changes in operating assets and liabilities, net:
Changes in:
Accounts receivable		4,481,129		13,498,542		(1,960,907)		1,820,501
Inventories		(15,972,829)		(16,946,534)		(38,850,545)		(20,836,483)
Prepaid expenses and other current assets		(245,248)		(974,732)		(377,920)		72,841
Other non-current assets		-		(140,569)
Other non-current asset						(4,963)		-
Accounts payable		(7,323,842)		1,632,353		25,606,471		10,098,122
Accounts payable - related parties		(318,428)		(1,021,524)		(216,112)		3,462,649
Deferred revenue		60,298		(163,211)		(614,523)		(151,463)
Accrued expenses and other current liabilities		(770,337)		(277,084)		(67,000)		(1,150,794)
Other non-current liabilities		(67,915)		(31,311)		148,147		(61,677)
Net cash used in operating activities		(16,985,511)		(3,333,662)		(16,669,045)		(5,985,615)

CASH FLOWS FROM INVESTING ACTIVITIES
Additions to property, plant and equipment		(1,624,493)		(1,852,865)		(815,063)		(1,264,395)
Proceeds from disposal of property, plant and equipment		6,000		28,100		46,218		-
Purchase of marketable securities		-		(316,000)
Sale of marketable securities		-		439,038
Equity method investment		-		(439,038)
Additions to internal use software		(118,121)		(236,555)		-		(118,389)
Net cash used in investing activities		(1,736,614)		(2,377,320)		(768,845)		(1,382,784)

CASH FLOWS FROM FINANCING ACTIVITIES
Net proceeds from sale of common stock		-		13,309,716		22,519,216		-
Net proceeds from exercise of common stock options		602,083		34,566		-		602,083
Taxes paid related to net share settlements of stock-based compensation awards		(107,495)		(83,803)		(113,688)		(75,083)
Borrowings and repayments on lines of credit, net		19,325,988		7,822,160		38,574		5,646,664
Repayment of contingent consideration obligation						(2,500,000)		-
Borrowings of long-term debt		89,717		601,341		12,500,000		88,150
Debt issuance costs						(257,964)		-
Repayments of long-term debt		(209,454)		(1,974,582)		(10,113,415)		(169,598)
Repayments of convertible debt		(4,721,551)		(11,274,679)		-		(3,427,837)
Net cash provided by financing activities		14,979,288		8,434,719		22,072,723		2,664,379

EFFECT OF EXCHANGE RATE CHANGES ON CASH		158,996		8,427		74,860		(92,185)

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS		(3,583,841)		2,732,164
NET INCREASE (DECREASE) IN CASH & CASH EQUIVALENTS						4,709,693		(4,796,205)

CASH AND CASH EQUIVALENTS, beginning of the period		6,904,500		3,535,458		745,001		6,904,500

CASH AND CASH EQUIVALENTS, end of period	$	3,320,659	$	6,267,622	$	5,454,694	$	2,108,295

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION

Cash paid during the period for:
Interest	$	1,039,100	$	922,561	$	776,882	$	823,844
Income taxes		194,886		205,225		42,244		148,019

S&W Seed Company, a Nevada corporation (the "Company"), began as S&W Seed Company, a general partnership, in 1980 and was originally in the business of breeding, growing, processing and selling alfalfa seed. We then incorporated a corporation with the same name in Delaware in October 2009, which is the successor entity to Seed Holding, LLC, having purchased a majority interest in the general partnership between June 2008 and December 2009. Following the Company's initial public offering in May 2010, the Company purchased the remaining general partnership interests and became the sole owner of the general partnership's original business. Seed Holding, LLC remains a consolidated subsidiary of the Company.

In December 2011, the Company reincorporated in Nevada as a result of a statutory short-form merger of the Delaware corporation into its wholly-owned subsidiary, S&W Seed Company, a Nevada corporation.

On April 1, 2013, the Company, together with its wholly-owned subsidiary, S&W Seed Australia Pty Ltd, an Australia corporation ("S&W Australia"), consummated an acquisition of all of the issued and outstanding shares of Seed Genetics International Pty Ltd, an Australia corporation ("SGI"), from SGI's shareholders.

Since its establishment, the Company, including its predecessor entities, has been principally engaged in breeding, growing, processing and selling agricultural seeds, primarily alfalfa seed. The Company owns seed cleaning and processing facilities, which are located in Five Points, California, Nampa, Idaho and ~~Nampa, Idaho.~~Keith, South Australia. The Company's seed products are primarily grown under contract by farmers. The Company began its stevia initiative in fiscal year 2010 and is currently focused on breeding improved varieties of stevia and developing marketing and distribution programs for its stevia products.

The Company has also been actively engaged in expansion initiatives through a combination of organic growth and strategic acquisitions, including in December 31, 2014, when the Company purchased certain alfalfa research and production facilities and conventional (non-GMO) alfalfa germplasm assets and assumed certain related liabilities ("the Pioneer Acquisition") of Pioneer Hi-Bred International, Inc. ("DuPont Pioneer").

More recently, in May 2016, the Company acquired the assets and business of SV Genetics, a private Australian company specializing in the breeding and licensing of proprietary hybrid sorghum and sunflower seed germplasm, which represented the Company's initial effort to diversify its product portfolio beyond alfalfa seed and stevia.

The Company's operations span the world's alfalfa seed production regions with operations in the San Joaquin and Imperial Valleys of California, five other U.S. states, Australia, and three provinces in Canada, and the Company sells its seed products in more than 30 countries around the globe.

The Company maintains its accounting records on an accrual basis in accordance with accounting principles generally accepted in the United States of America ("GAAP").

The consolidated financial statements include the accounts of Seed Holding, LLC and its other wholly-owned subsidiaries, S&W Australia, which owns 100% of SGI, and Stevia California, LLC. All significant intercompany balances and transactions have been eliminated.

The Company has prepared the accompanying consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") for interim financial reporting. These consolidated financial statements are unaudited and, in the Company's opinion, include all adjustments, consisting of normal recurring adjustments and accruals, necessary for a fair presentation of the Company's consolidated balance sheets, statements of operations, comprehensive income (loss), cash flows and stockholders' equity for the periods presented. Operating results for the periods presented are not necessarily indicative of the results to be expected for the full year ending June 30, ~~2017.~~2018. Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted in accordance with the rules and regulations of the SEC. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Company's Annual Report on Form 10-K for the year ended June 30, ~~2016,~~2017, as filed with the SEC.

The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates are adjusted to reflect actual experience when necessary. Significant estimates and assumptions affect many items in the financial statements. These include allowance for doubtful trade receivables, inventory valuation, asset impairments, provisions for income taxes, grower accruals (an estimate of amounts payable to farmers who grow seed for the Company), contingent consideration obligations, derivative liabilities, contingencies and litigation. Significant estimates and assumptions are also used to establish the fair value and useful lives of depreciable tangible and certain intangible assets, goodwill as well as valuing stock-based compensation. Actual results may differ from those estimates and assumptions, and such results may affect income, financial position or cash flows.

The Company's revenue is principally derived from the sale of alfalfa seed, the market for which is highly competitive. The Company depends on a core group of significant customers. One customer accounted for ~~77%~~75% and ~~65%~~66% of its revenue for the three months ended ~~March~~December 31, 2017 and 2016, respectively. One customer accounted for ~~59%~~58% and ~~50%~~49% of its revenue for the ~~nine~~six months ended ~~March~~December 31, 2017 and 2016, respectively.

Two customers accounted for ~~56%~~50% of the Company's accounts receivable at ~~March~~December 31, 2017. ~~One customer~~Two customers accounted for ~~35%~~52% of the Company's accounts receivable at June 30, ~~2016.~~2017.

In addition, the Company sells a substantial portion of its products to international customers. Sales ~~direct~~ to international ~~customers~~markets represented ~~20%~~23% and ~~34%~~30% of revenue during the three months ended ~~March~~December 31, 2017 and 2016, respectively. Sales ~~direct~~ to international ~~customers~~markets represented ~~36%~~38% and ~~44%~~46% of revenue during the ~~nine~~six months ended ~~March~~December 31, 2017 and 2016, respectively. The net book value of fixed assets located outside the United States was ~~18%~~19% and ~~17%~~19% of total assets at ~~March~~December 31, 2017 and June 30, ~~2016,~~2017, respectively. Cash balances located outside of the United States may not be insured and totaled ~~$331,687~~$1,209,181 and ~~$1,923,290~~$192,879 at ~~March~~December 31, 2017 and June 30, ~~2016,~~2017, respectively.

		Three Months Ended March 31,						Nine Months Ended March 31,						Three Months Ended December 31,						Six Months Ended December 31,
		2017			2016			2017			2016			2017			2016			2017			2016
United States	$	16,850,655	80%	$	16,596,810	66%	$	36,633,044	64%	$	34,092,324	56%	$	15,740,706	77%	$	16,858,325	70%	$	19,265,254	62%	$	19,782,389	54%
Saudi Arabia		1,051,593	5%		3,821,011	15%		6,273,365	11%		13,452,368	22%
China		790,486	4%		211,967	1%		889,834	2%		431,288	1%
Mexico		549,420	3%		743,617	3%		4,294,447	7%		3,830,117	6%		1,664,618	8%		1,404,133	6%		4,380,626	14%		3,745,027	10%
Argentina		316,046	2%		704,059	3%		2,881,050	5%		2,272,120	4%		1,183,423	6%		1,677,035	7%		2,742,619	9%		2,565,004	7%
Egypt		394,560	2%		502,250	2%		677,520	1%		502,090	1%
Peru		297,438	1%		363,297	1%		821,213	1%		1,529,304	2%
Libya														563,673	3%		-	0%		752,673	2%		-	0%
Saudi Arabia														513,000	2%		1,843,949	8%		844,908	3%		5,221,772	15%
Australia														438,468	2%		71,175	0%		557,998	2%		790,636	2%
South Africa														338,993	2%		634,768	2%		467,342	1%		636,870	2%
Sudan														-	0%		67,016	0%		447,500	1%		67,016	0%
Other		762,045	3%		2,070,768	9%		5,017,087	9%		5,300,337	8%		89,915	0%		1,669,343	7%		1,785,592	6%		3,666,603	10%
Total	$	21,012,243	100%	$	25,013,779	100%	$	57,487,560	100%	$	61,409,948	100%	$	20,532,796	100%	$	24,225,744	100%	$	31,244,512	100%	$	36,475,317	100%

The Company translates its foreign operations' assets and liabilities denominated in foreign currencies into U.S. dollars at the current rates of exchange as of the balance sheet date and income and expense items at the average exchange rate for the reporting period. Translation adjustments resulting from exchange rate fluctuations are recorded in the cumulative translation account, a component of accumulated other comprehensive income. Gains or losses from foreign currency transactions are included in the consolidated statement of operations.

The Company derives its revenue primarily from sale of seed and other crops and milling services. Revenue from seed and other crop sales is recognized when risk and title to the product is transferred to the customer. ~~No customer has a right of return.~~

The Company recognizes revenue from milling ~~and other~~ services ~~provided~~ according to the terms of the ~~underlying agreement~~sales agreements and when delivery has occurred, performance is complete and pricing is fixed or determinable at the time of sale.

Additional conditions for recognition of revenue for all sales include the requirements that the collection of sales proceeds must be reasonably assured based on historical experience and current market conditions, the sales price is fixed and determinable and that there must be no further performance obligations under the sale.

The Company records purchasing and receiving costs, inspection costs and warehousing costs in cost of revenue. When the Company is required to pay for outward freight and/or the costs incurred to deliver products to its customers, the costs are included in cost of revenue.

For financial statement presentation purposes, the Company considers time deposits, certificates of deposit and all highly liquid investments with original maturities of three months or less to be cash and cash equivalents. At times, cash and cash equivalents balances exceed amounts insured by the Federal Deposit Insurance Corporation.

The Company provides an allowance for doubtful trade receivables equal to the estimated uncollectible amounts. That estimate is based on historical collection experience, current economic and market conditions and a review of the current status of each customer's trade accounts receivable. The allowance for doubtful trade receivables was ~~$177,295~~$526,495 at ~~March~~December 31, 2017 and June 30, ~~2016.~~2017.

Inventories are stated at the lower of cost or market, and an inventory reserve permanently reduces the cost basis of inventory. Inventories are valued as follows: Actual cost is used to value raw materials such as packaging materials, as well as goods in process. Costs for substantially all finished goods, which include the cost of carryover crops from the previous year, are valued at actual cost. Actual cost for finished goods includes plant conditioning and packaging costs, direct labor and raw materials and manufacturing overhead costs based on normal capacity. The Company records abnormal amounts of idle facility expense, freight, handling costs and wasted material (spoilage) as current period charges and allocates fixed production overhead to the costs of finished goods based on the normal capacity of the production facilities.

The Company's subsidiary, SGI, does not fix the final price for seed payable to its growers until the completion of a given year's sales cycle pursuant to its standard contract production agreement. SGI records an estimated unit price; accordingly, inventory, cost of revenue and gross profits are based upon management's best estimate of the final purchase price to growers.

Inventory is periodically reviewed to determine if it is marketable, obsolete or impaired. ~~A reserve is recorded against inventory~~Inventory that is determined to be obsolete or impaired is written off to expense at the time the impairment is identified. Because the germination rate, and therefore the quality, of alfalfa seed improves over the first year of proper storage, inventory obsolescence for alfalfa seed is not a material concern. The Company sells its inventory to distributors, dealers and directly to growers.

		March 31,		June 30,		December 31,		June 30,
		2017		2016		2017		2017
Raw materials and supplies	$	224,805	$	241,268	$	235,910	$	266,551
Work in progress and growing crops		6,322,371		3,120,485
Work in progress						23,890,021		5,603,825
Finished goods		31,505,072		18,484,377		46,361,054		25,619,569
	$	38,052,248	$	21,846,130	$	70,486,985	$	31,489,945

Property, plant and equipment is depreciated using the straight-line method over the estimated useful life of the asset - periods of ~~7-28~~5-28 years for buildings, 3-20 years for machinery and equipment, and 3-5 years for vehicles.

Intangible assets acquired in business acquisitions are reported at their initial fair value less accumulated amortization. Intangible assets are amortized using the straight-line method over the estimated useful life of the asset. Periods of 10-30 years for technology/IP/germplasm, 10-20 years for customer relationships and trade names and ~~2-20~~3-20 for other intangible assets. The weighted average estimated useful lives are 2426 years for technology/IP/germplasm, 18 years for customer relationships and 20 years for trade names and ~~19 years for~~ other intangible assets.

Goodwill originated from acquisitions of Imperial Valley Seeds, Inc. ("IVS") and SGI during the fiscal year 2013, the acquisition of the alfalfa business from DuPont Pioneer in fiscal year 2015 and the acquisition of assets of SV Genetics in May 2016. Goodwill is assessed at least annually, or when certain triggering events occur, for impairment using fair value measurement techniques. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. If management concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, management conducts a two-step quantitative goodwill impairment test. The first step of the goodwill impairment test is used to identify potential impairment by comparing the fair value of a reporting unit with its carrying amount, including goodwill. The Company uses ~~a discounted cash flow methodology~~market capitalization to estimate the fair value of a reporting unit. A discounted cash flow analysis requires various judgmental assumptions including assumptions about future cash flows, growth rates and discount rates. The assumptions about future cash flows and growth rates are based on the Company's budget and long-term plans. Discount rate assumptions are based on an assessment of the risk inherent in theits one reporting unit. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired, and the second step of the impairment test is unnecessary.

If the carrying amount of a reporting unit exceeds its fair value, the second step of the goodwill impairment test is performed to measure the amount of impairment loss, if any. The second step of the goodwill impairment test compares the implied fair value of the reporting unit's goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit's goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination. That is, the fair value of the reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the purchase price paid to acquire the reporting unit. The Company performed a quantitative assessment of goodwill at June 30, 2017 and determined that goodwill was not impaired.

Investee companies that are not consolidated, but over which the Company exercises significant influence, are accounted for under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an investee depends on an evaluation of several factors including, among others, representation on the investee company's board of directors and ownership level, which is generally a 20% to 50% interest in the voting securities of the investee company. Under the equity method of accounting, an investee company's accounts are not reflected within the Company's consolidated balance sheets and statements of operations; however, the Company's share of the earnings or losses of the investee company is reflected in the caption ``Loss on equity method investment'' in the consolidated statements of operations. The Company's carrying value in an equity method investee company is included in the Company's consolidated balance sheets. When the Company's carrying value in an equity method investee company is reduced to zero, no further losses are recorded in the Company's consolidated financial statements unless the Company guaranteed obligations of the investee company or has committed additional funding. When the investee company subsequently reports income, the Company will not record its share of such income until it equals the amount of its share of losses not previously recognized.

Loss on equity method investment totaled $95,591 and $28,916 for the three months ended March 31, 2017 and 2016, respectively. Loss on equity method investment totaled $144,841 and $252,619 for the nine months ended March 31, 2017 and 2016, respectively. This represents the Company's 50% share of losses incurred by the joint corporation (S&W Semillas S.A.) in Argentina during the two periods.

Investee companies not accounted for under the consolidation or the equity method of accounting are accounted for under the cost method of accounting. Under this method, the Company's share of the earnings or losses of such investee companies is not included in the consolidated balance sheet or statement of operations. However, impairment charges are recognized in the consolidated statement of operations. If circumstances suggest that the value of the investee company has subsequently recovered, such recovery is not recorded.

The Company is engaged in ongoing research and development ("R&D") of proprietary seed and stevia varieties. All R&D costs must be charged to expense as incurred. Accordingly, internal R&D costs are expensed as incurred. Third-party R&D costs are expensed when the contracted work has been performed or as milestone results have been achieved. The costs associated with equipment or facilities acquired or constructed for R&D activities that have alternative future uses are capitalized and depreciated on a straight-line basis over the estimated useful life of the asset.

Deferred tax assets and liabilities are determined based on differences between the financial statement and tax basis of assets and liabilities, as well as a consideration of net operating loss and credit carry forwards, using enacted tax rates in effect for the period in which the differences are expected to impact taxable income. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount that is more likely than not to be realized. The Company's effective tax rate for the three and six months ended December 31, 2017 has been effected by the valuation allowance on the Company's deferred tax assets.

Basic net income (loss) per common share ("EPS"), is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period.

Diluted EPS is calculated by adjusting both the numerator (net income (loss)) and the denominator (weighted-average number of shares outstanding) for the dilutive effects of potentially dilutive securities, including options, restricted stock awards, convertible debt and common stock warrants.

The calculation of Basic and Diluted EPS is shown in the table below. Classes of securities identified in the table with no adjustments in the calculation of Diluted EPS were determined to be antidilutive for the applicable periods.

		Three Months Ended				Nine Months Ended				Three Months Ended				Six Months Ended
		March 31,				March 31,				December 31,				December 31,
		2017		2016		2017		2016		2017		2016		2017		2016

Numerator:
Net income (loss)	$	1,327,240	$	567,873	$	(730,961)	$	55,426	$	(399,887)	$	1,158,958	$	(2,217,393)	$	(2,058,198)

Numerator for basis EPS		1,327,240		567,873		(730,961)		55,426		(399,887)		1,158,958		(2,217,393)		(2,058,198)

Effect of dilutive securities:
Convertible debt		-		-		-		-
Warrants		(1,009,901)		-		(841,400)		-		-		(959,200)		-		-
		(1,009,901)		-		(841,400)		-		-		(959,200)		-		-

Numerator for diluted EPS	$	317,339	$	567,873	$	(1,572,361)	$	55,426	$	(399,887)	$	199,758	$	(2,217,393)	$	(2,058,198)

Denominator:
Denominator for basic EPS -
weighted-average shares		17,963,598		15,420,308		17,630,906		14,278,107
Denominator for basic EPS - weighted-average shares										21,130,960		17,821,547		20,643,973		17,467,370

Effect of dilutive securities:
Employee stock stock options		-		-		-		-
Employee stock options										-		-		-		-
Employee restricted stock units		-		-		-		-		-		-		-		-
Convertible debt		-		-		-		-
Warrants		15,579		-		87,337		-		-		174,674		-		-
Dilutive potential common shares		15,579		-		87,337		-		-		174,674		-		-
Denominator for diluted EPS -
adjusted weighted average shares
and assumed conversions		17,979,177		15,420,308		17,718,243		14,278,107
Denominator for diluted EPS - adjusted weighted average shares and assumed conversions										21,130,960		17,996,221		20,643,973		17,467,370


Basic EPS	$	0.07	$	0.04	$	(0.04)	$	0.00	$	(0.02)	$	0.07	$	(0.11)	$	(0.12)
Diluted EPS	$	0.02	$	0.04	$	(0.09)	$	0.00	$	(0.02)	$	0.01	$	(0.11)	$	(0.12)

The Company evaluates its long-lived assets for impairment annually or more often if events and circumstances warrant. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses or a forecasted inability to achieve break-even operating results over an extended period. The Company evaluates the recoverability of long-lived assets based upon forecasted undiscounted cash flows. Should impairment in value be indicated, the carrying value of long-lived assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset.

The Company's subsidiary, SGI, is exposed to foreign currency exchange rate fluctuations in the normal course of its business, which the Company at times manages through the use of foreign currency forward contracts.

The Company has entered into certain derivative financial instruments (specifically foreign currency forward contracts), and accounts for these instruments in accordance with ASC Topic 815, "Derivatives and Hedging", which establishes accounting and reporting standards requiring that derivative instruments be recorded on the balance sheet as either an asset or liability measured at fair value. The Company's foreign currency contracts are not designated as hedging instruments under ASC 815; accordingly, changes in the fair value are recorded in current period earnings.

The Company reviews the terms of the common stock, warrants and convertible debt it issues to determine whether there are embedded derivative instruments, including embedded conversion options and redemption options, which are required to be bifurcated and accounted for separately as derivative financial instruments.

The Company discloses assets and liabilities that are recognized and measured at fair value, presented in a three-tier fair value hierarchy, as follows:

The assets acquired and liabilities assumed in the DuPont Pioneer Acquisition were valued at fair value on a non-recurring basis as of December 31, 2014. The assets acquired and liabilities assumed in the SV Genetics Acquisition were valued at fair value on a non-recurring basis as of May 26, 2016. No assets or liabilities were valued at fair value on a non-recurring basis as of ~~March~~December 31, 2017 or June 30, ~~2016.~~2017.

The carrying value of cash and cash equivalents, accounts payable, short-term and all long-term borrowings, ~~other than the convertible debentures,~~ as reflected in the consolidated balance sheets, approximate fair value because of the short-term maturity of these instruments or interest rates commensurate with market rates. There have been no changes in operations and/or credit characteristics since the date of issuance that could impact the relationship between interest rate and market rates. ~~At March 31, 2017, the fair value and carrying value of the convertible debentures was zero.~~

At June 30, 2016, the fair value and carrying value of the convertible debentures was $7,829,671 and $6,840,608 respectively. The fair value was calculated using a discounted cash flow model and utilized a 10% discount rate that is commensurate with market rates given the remaining term, principal repayment schedule and outstanding balance. The convertible debentures are categorized as Level 3 in the fair value hierarchy. The Company used a discounted cash flows approach to measure the fair value using Level 3 inputs.

Assets and liabilities that are recognized and measured at fair value on a recurring basis are categorized as follows:

		Fair Value Measurements as of March 31, 2017 Using:						Fair Value Measurements as of December 31, 2017 Using:
		Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
Foreign exchange contract asset	$	-	$	173,192	$	-	$	-	$	68,172	$	-
Contingent consideration obligations		-		-		2,346,091		-		-		-
Derivative warrant liabilities		-		-		3,512,700		-		-		-
Total	$	-	$	173,192	$	5,858,791	$	-	$	68,172	$	-


								Fair Value Measurements as of June 30, 2017 Using:
								Level 1		Level 2		Level 3
Foreign exchange contract asset							$	-	$	166,629	$	-
Contingent consideration obligations								-		-		2,500,000
Derivative warrant liabilities								-		-		2,836,600
Total							$	-	$	166,629	$	5,336,600

~~There were no transfers in or out of Level 3 during~~During the ~~three and nine~~six months ended ~~March~~December 31, 2017, ~~and 2016.~~

~~Reclassifications~~a change in derivative warrant liability of $431,300 was recorded in earnings. Upon expiration of the round-down pricing protection on December 31, 2017, the warrants were reclassified from derivative warrant liabilities to equity.

~~Certain reclassifications have been made~~During the six months ended December 31, 2017, there was no change in the contingent consideration obligations. The DuPont contingent consideration was settled on December 1, 2017. Refer to ~~prior period amounts to conform to current period presentation. The reclassifications had no effect on net income (loss), cash flows or stockholders' equity.~~Note 5 for further discussion.

~~In March 2016, the FASB issued Accounting Standards Update No. 2016-09,~~~~Improvements to Employee Share-Based Payment Accounting~~("ASU 2016-09"). This standard was issued as part of the FASB's Simplification Initiative that involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. Some of the areas for simplification apply only to nonpublic entities. For public business entities, ASU 2016-09 is effective for annual periods beginning after December 15, 2016 and interim periods within those annual periods. The method of adoption is dependent on the specific aspect of accounting addressed in this new guidance. Early adoption is permitted in any interim or annual period. The Company is evaluating the impact of the adoption of ASU 2016-09 on its consolidated financial statements.

In January 2017, the FASB issued Accounting Standards Update No. 2017-04,Simplifying the Test for Goodwill Impairment ("ASU 2017-04"). This standard eliminates Step 2 from the goodwill impairment test. Instead, an entity should perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount and recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, not to exceed the total amount of goodwill allocated to the reporting unit. ASU 2017-04 is effective for the Company beginning July 1, 2020. The adoption is not expected to have a material impact on the consolidated financial statements.

In August 2016, the FASB issued Accounting Standards Update No. 2016-15, Classification of Certain Cash Receipts and Cash Payments ("ASU 2016-15"). This standard addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. ASU 2016-15 is effective for the Company beginning July 1, 2018 and the Company is currently evaluating the impact that ASU 2016-15 will have on its consolidated financial statements.

In March 2016, the FASB issued Accounting Standards Update No. 2016-09,Improvements to Employee Share-Based Payment Accounting("ASU 2016-09"). This standard was issued as part of the FASB's Simplification Initiative that involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. Some of the areas for simplification apply only to nonpublic entities. For public business entities, ASU 2016-09 is effective for annual periods beginning after December 15, 2016 and interim periods within those annual periods. The method of adoption is dependent on the specific aspect of accounting addressed in this new guidance. Early adoption is permitted in any interim or annual period. The Company adopted ASU 2016-09 in the first quarter of the fiscal year ended June 30, 2018. The adoption did not have a material impact on the consolidated financial statements.

In February 2016, the FASB issued Accounting Standards Update No. 2016-02:Leases("ASU 2016-02"). This standard amends various aspects of existing accounting guidance for leases, including the recognition of a right-of-use asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of operations. This standard also introduces new disclosure requirements for leasing arrangements. For public business entities, ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The new standard must be adopted using a modified retrospective approach, and provides for certain practical expedients. The Company is evaluating the impact of the adoption of ASU 2016-02 on its consolidated financial statements and related disclosures.

In May 2014, the FASB issued Accounting Standards Update No. 2014-09,Revenue from Contracts with Customers(``ASU 2014-09''). This standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most existing revenue recognition guidance under U.S. GAAP. The core principle of the guidance is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASU 2014-09 also requires enhanced disclosures about the nature, amount, timing, and uncertainty of revenues and cash flows arising from contracts with customers. The FASB recently issued several amendments to the standard, including clarifications on disclosure of prior-period performance obligations and remaining performance obligations. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. However, in August 2015, the FASB issued ASU 2015-14,Revenue from Contracts with Customers: Deferral of the Effective Datethat defers the effective date of ASU 2014-09 for all public business entities by one year. As a result, ASU 2014-09 is effective for fiscal years beginning after December 15, 2017 including interim periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. The Company is evaluating the impact of the adoption of ASU 2014-09 on its consolidated financial statements and related disclosures.

On May 26, 2016, the Company purchased the assets and business of SV Genetics Pty Ltd ("SV Genetics"), a private Australian company specializing in the breeding and licensing of proprietary hybrid sorghum and sunflower seed germplasm (the "SV Genetics Acquisition"). The acquisition expanded and diversified the Company's product offerings and provided access to new distribution channels.

As consideration for the SV Genetics Acquisition, the Company paid the following amounts at closing: $1.0 million in cash and 225,088 shares of the Company's common stock. The fair value of the shares of the Company's common stock was determined based on the closing market price of the Company's common stock on the acquisition date and a 5% discount because of the lack of marketability that market participants would consider when estimating the fair value of the common stock issued. The terms of the SV Genetics Acquisition further provide for a potential earn-out payment of up to $3.3 million, payable in cash or the Company's common stock, in the sole discretion of the Company, based on the acquired business achieving 150% of a net income target of $4.2 million for the combined 2018 and 2019 fiscal years. Any earn-out payment, if paid in stock, will be based upon the trailing volume weighted average price on the day immediately preceding the payment of the earn-out. The earn-out payment, if any, will be made in September 2019.

The SV Genetics Acquisition has been accounted for as a business combination, and the Company valued and recorded all assets acquired and liabilities assumed at their estimated fair values on the date of the SV Genetics Acquisition.

~~The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date of May 26, 2016:~~

~~The acquisition-date fair value of the consideration transferred consisted of the following:~~

The excess of the purchase price over the fair value of the net assets acquired, amounting to $796,064, was recorded as goodwill on the consolidated balance sheet. The primary item that generated goodwill was the premium paid by the Company for the ability to control the acquired business and the technology / germplasm. Goodwill is not amortized for financial reporting purposes, but is amortized for tax purposes.

Management assigned fair values to the identifiable intangible assets through a combination of the relief from royalty method, the multi-period excess earnings method, and the with-and-without method. The contingent consideration requires the Company to pay up to an additional $3.3 million, if the acquired business achieves 150% of a net income target of $4.2 million for the combined 2018 and 2019 fiscal years. The fair value of the contingent consideration arrangement at the acquisition date was $135,324. The fair value of the contingent consideration was estimated using a Monte Carlo simulation model. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement. The key assumptions in applying the Monte Carlo simulation were as follows: 40.0% present value discount factor and an underlying net income volatility of 87.9%. As of March 31, 2017, the estimated fair value of the contingent consideration was zero. The values and useful lives of the acquired SV Genetics intangibles are as follows:

The following table summarizes the activity of goodwill for the ~~nine~~six months ended ~~March~~December 31, 2017 and the year ended June 30, ~~2016,~~2017, respectively.

		Balance at						Foreign Currency		Balance at		Balance at						Balance at
		July 1, 2016		Additions		Amortization		Translation		March 31, 2017		July 1, 2017		Additions		Amortization		December 31, 2017
Trade name	$	1,328,786	$	-	$	(63,360)	$	-	$	1,265,426	$	1,244,306	$	-	$	(42,240)	$	1,202,066
Customer relationships		1,359,371		-		(75,906)		-		1,283,465		1,258,163		-		(50,604)		1,207,559
Non-compete		198,999		-		(72,723)		-		126,276		102,035		-		(31,032)		71,003
GI customer list		85,967		-		(5,373)		-		80,594		78,803		-		(3,582)		75,221
Supply agreement		1,229,047		-		(56,724)		-		1,172,323		1,153,415		-		(37,816)		1,115,599
Distribution agreement		7,113,253		-		(288,375)		-		6,824,878		6,728,753		-		(192,250)		6,536,503
Production agreement		335,002		-		(167,499)		-		167,503		111,670		-		(111,666)		4
Grower relationships		1,964,024		-		(79,056)		-		1,884,968		1,858,616		-		(52,704)		1,805,912
Intellectual property		22,870,760		-		(858,916)		-		22,011,844		21,725,539		-		(572,610)		21,152,929
Internal use software		521,593		118,122		-		-		639,715		677,779		-		(33,888)		643,891
											$	34,939,079	$	-	$	(1,128,392)	$	33,810,687
	$	37,006,802	$	118,122	$	(1,667,932)	$	-	$	35,456,992

		Balance at						Foreign Currency		Balance at		Balance at						Balance at
		July 1, 2015		Additions		Amortization		Translation		June 30, 2016		July 1, 2016		Additions		Amortization		June 30, 2017
Trade name	$	1,377,840	$	45,000	$	(82,208)	$	(11,846)	$	1,328,786	$	1,328,786	$	-	$	(84,480)	$	1,244,306
Customer relationships		968,619		462,000		(60,314)		(10,934)		1,359,371		1,359,371		-		(101,208)		1,258,163
Non-compete		301,354		30,000		(125,815)		(6,540)		198,999		198,999		-		(96,964)		102,035
GI customer list		93,131		-		(7,164)		-		85,967		85,967		-		(7,164)		78,803
Supply agreement		1,304,679		-		(75,632)		-		1,229,047		1,229,047		-		(75,632)		1,153,415
Distribution agreement		7,497,750		-		(384,497)		-		7,113,253		7,113,253		-		(384,500)		6,728,753
Production agreement		558,334		-		(223,332)		-		335,002		335,002		-		(223,332)		111,670
Grower relationships		2,183,485		-		(120,481)		(98,980)		1,964,024		1,964,024		-		(105,408)		1,858,616
Intellectual property		23,719,724		536,000		(1,159,656)		(225,308)		22,870,760		22,870,760		-		(1,145,221)		21,725,539
Internal use software		162,417		359,176		-		-		521,593		521,593		156,186		-		677,779
	$	38,167,333	$	1,432,176	$	(2,239,099)	$	(353,608)	$	37,006,802	$	37,006,802	$	156,186	$	(2,223,909)	$	34,939,079

Amortization expense totaled ~~$555,977~~$555,471 and ~~$558,358~~$555,977 for the three months ended ~~March~~December 31, 2017 and 2016, respectively. Amortization expense totaled ~~$1,667,932~~$1,128,392 and ~~$1,673,048~~$1,111,954 for the ~~nine~~six months ended ~~March~~December 31, 2017 and 2016, respectively. Estimated aggregate remaining amortization is as follows:

		March 31,		June 30,		December 31,		June 30,
		2017		2016		2017		2017

Land and improvements	$	3,091,558	$	2,908,501	$	2,090,069	$	2,223,674
Buildings and improvements		6,391,988		6,192,522		6,784,964		6,401,277
Machinery and equipment		5,156,871		4,781,586		5,680,599		5,435,542
Vehicles		1,080,354		1,080,354		1,166,596		1,005,455
Construction in progress		1,149,349		256,935		2,170,844		2,196,513
Total property, plant and equipment		16,870,120		15,219,898		17,843,072		17,262,461

Less: accumulated depreciation		(3,404,315)		(2,619,792)		(4,212,949)		(3,680,885)

Property, plant and equipment, net	$	13,465,805	$	12,600,106	$	13,630,123	$	13,581,576

Depreciation expense totaled ~~$242,582~~$315,510 and ~~$237,704~~$286,477 for the three months ended ~~March~~December 31, 2017 and 2016, respectively. Depreciation expense totaled ~~$807,778~~$630,842 and ~~$703,053~~$565,197 for the ~~nine~~six months ended ~~March~~December 31, 2017 and 2016, respectively.

Total debt outstanding, excluding convertible debt addressed in Note 7,6, are presented on the consolidated balance sheet as follows:

		March 31,		June 30,		December 31,		June 30,
		2017		2016		2017		2017
Working capital lines of credit
KeyBank	$	28,975,875	$	12,308,828	$	21,649,089	$	18,695,896
National Australia Bank Limited		7,190,622		4,378,645		6,115,026		8,703,888
Total working capital lines of credit		36,166,497		16,687,473
Debt issuance costs						(171,512)		-
Total working capital lines of credit, net					$	27,592,603	$	27,399,784

Current portion of long-term debt
Keith facility (building loan) - National Australia Bank Limited		-		37,205	$	3,901	$	-
Keith facility (machinery & equipment loans) - National Australia Bank Limited		161,411		137,889		218,239		209,664
Unsecured subordinate promissory note - related party		100,000		100,000
Unsecured subordinate promissory note						100,000		100,000
Promissory note - DuPont Pioneer		10,000,000		-		-		10,000,000
Total current portion		10,261,411		275,094
Secured real estate note - Conterra						112,711		-
Debt issuance costs						(77,563)		-
Secured equipment note - Conterra						18,473		-
Debt issuance costs						(16,897)		-
Total current portion, net						358,864		10,309,664

Long-term debt, less current portion
Keith facility (building loan) - National Australia Bank Limited		496,828		446,454		444,713		499,524
Keith facility (machinery & equipment loans) - National Australia Bank Limited		543,586		567,879		545,285		596,631
Unsecured subordinate promissory note - related party		-		100,000
Promissory note - DuPont Pioneer		-		10,000,000
Total long-term portion		1,040,414		11,114,333
Total debt	$	11,301,825	$	11,389,427
Secured real estate note - Conterra						10,287,289		-
Debt issuance costs						(138,917)		-
Secured equipment note - Conterra						2,081,527		-
Debt issuance costs						(16,706)		-
Total long-term portion, net						13,203,191		1,096,155
Total debt, net					$	13,562,055	$	11,405,819

On September 22, 2015, the Company and KeyBank National Association ("KeyBank") entered into a credit and securities agreement and related agreements with respect to a $20,000,000 aggregate principal amount revolving credit facility (the "KeyBank Credit Facility")~~. All~~, the principal amount of which was increased to $35,000,000 pursuant to a Fourth Amendment Agreement (the "Fourth Amendment") on September 13, 2017, as more fully described below. Under the Fourth Amendment, all amounts of unpaid principal and interest due under the KeyBank Credit Facility must be paid in full on or before September ~~21, 2017.~~

On October 4, 2016, the Company and KeyBank entered into a Second Amendment Agreement effective September 30, 2016 (the "Second Amendment"). The purpose of the Second Amendment was to provide certain temporary changes to the terms of the KeyBank Credit Facility, including: (i) temporarily increasing the borrowing capacity from $20.0 million to (a) up to $25.0 million between October 1, 2016 and November 30, 2016 and (b) up to $30.0 million from February 1, 2017 through March 31, 2017; (ii) temporarily allowing for a $4.0 million over-advance beyond the amounts otherwise available based on the borrowing base calculations, which ~~will be~~was available through February 28, 2017; and (iii) temporarily expanding the borrowing base by reducing the reserves that KeyBank may establish with respect to grower payables to 75% between August 31, 2016 and February 28, 2017.

On March 13, 2017, the Company entered into a Third Amendment Agreement (the " Third Amendment"). The purpose of the Third Amendment was to provide certain temporary changes to the terms of the KeyBank Credit Facility, including: (i) further extending the temporary period during which the Company may borrow, repay and reborrow up to $30.0 million in the aggregate under the credit facility until April 21, 2017; and (ii) retroactively and temporarily allowing for over-advances, beyond amounts otherwise available based on the borrowing base calculations under the Credit Facility (a) of up to $3.5 million during the period from March 8, 2017 through March 10, 2017, (b) of up to $5.0 million during the period from March 11, 2017 through March 17, 2017, (c) of up to $6.0 million during the period from March 18, 2017 through March 24, 2017, (d) of up to $7.0 million during the period from March 25, 2017 through March 31, 2017 and (e) of up to $8.5 million during the period from April 1, 2017 through as late as April 20, 2017.

~~Subject~~On September 13, 2017, the Company and Key Bank entered into the Fourth Amendment, pursuant to which the ~~temporary changes effected by~~maturity date was extended to September 12, 2019 and the ~~Second~~principal amount that the Company may borrow, repay and reborrow was increased to $35.0 million, subject to a requirement that the Company maintain a reduced loan balance of (i) not more than $20 million for at least 30 consecutive days over the prior 12 months (measured each quarter on a trailing 12 month basis) and (ii) not more than $25 million for at least 60 consecutive days over the prior 12 months (measured each quarter on a trailing 12 month basis). The Fourth Amendment ~~the KeyBank Credit Facility~~ generally establishes a borrowing base of up to 85% of eligible domestic accounts receivable ~~(90% if insured),~~and 90% of eligible foreign accounts receivable, plus up to 65% of eligible inventory, subject to lender reserves. Loans may be based on a Base Rate or Eurodollar Rate (which is increased by an applicable margin of 2%2.2% per annum), generally at the Company's option.

In the event of a default, at the option of KeyBank, the interest rate on all obligations owing will increase by 3% per annum over the rate otherwise applicable. The Company is required to maintain one or more lockbox or cash collateral accounts at KeyBank, in KeyBank's name, which provide for the collection and remittance of all proceeds from sales of Company product (which is collateral for the KeyBank Credit Facility) on a daily basis. Subject to certain exceptions, the KeyBank Credit Facility is secured by a first priority perfected security interest in all the Company's now owned and after acquired tangible and intangible assets as well as the assets of the Company's domestic subsidiaries, which have guaranteed the Company's obligations under the KeyBank Credit Facility. The KeyBank Credit Facility is further secured by a lien on, and a pledge of, 65% of the stock of S&W Australia Pty Ltd., the Company's wholly-owned subsidiary. With respect to its security interest and/or lien, KeyBank has entered into an intercreditor and subordination agreement with Hudson Bay Fund LP (as agent for the holders of the senior secured debentures issued by the Company in December 2014) and DuPont Pioneer. The KeyBank Credit Agreement contains customary representations and warranties, affirmative and negative covenants and customary events of default. The Company was in compliance with all covenants at ~~March~~December 31, 2017. The outstanding balance on the KeyBank Credit Facility was ~~$28,975,875~~$21,649,089 at ~~March~~December 31, 2017.

On October 1, 2012, the Company issued a five-year subordinated promissory note to IVS in the principal amount of $500,000 (the "IVS Note"), with a maturity date of October 1, 2017. The IVS Note accrues interest at a rate equal to one-month LIBOR at closing plus 2%, which equals 2.2%. Interest is payable in five annual installments, in arrears, on October 1 of each year. Amortizing payments of the principal of $100,000 will also be made on each October 1, with any remaining outstanding principal and accrued interest payable on the maturity date of the IVS Note. The outstanding balance on the IVS Note was $100,000 at ~~March~~December 31, 2017.

On December 31, 2014, the Company issued a three-year secured promissory note to DuPont Pioneer in the initial principal amount of $10,000,000 (the "Pioneer Note"), with a maturity date of December 31, 2017. The Pioneer Note ~~accrues~~accrued interest at 3% per annum. Interest iswas payable in three annual installments, in arrears, commencing on December 31, 2015. On December 31, 2014, the Company also issued contingent consideration to DuPont Pioneer which ~~requires~~required the Company to increase the principal amount of the Pioneer Note by up to an additional $5,000,000 if the Company ~~meets~~met certain performance metrics during the three-year period following December 31, 2014. The ~~fair value~~earn out payment to DuPont Pioneer was finalized in October 2017 and this amount of $2,500,000 was added to the Pioneer Note in October 2017. On December 1, 2017, the Company repaid the Pioneer Note. The repayment amount included the $2.5 million earn-out payment related to the Pioneer Acquisition that was added to the principal amount of the ~~contingent consideration arrangement was $2,290,850~~Pioneer Note in October 2017.

On November 30, 2017, the Company entered into a secured note financing transaction (the "Loan Transaction") with Conterra Agricultural Capital, LLC ("Conterra") for $12.5 million in gross proceeds. Pursuant to the Loan Transaction, the Company issued two secured promissory notes (the "Notes") to Conterra as follows:

The Notes and related documents include customary representations and warranties in addition to customary affirmative and negative covenants (including financial covenants), and customary events of default that permit Conterra to accelerate the Company's obligations under the Notes, including, among other things, that a default under one of the Notes would constitute a default under the other Note. On December 1, 2017, the Company used the proceeds from the Loan Transaction to repay the Pioneer Note.

SGI finances the purchase of most of its seed inventory from growers pursuant to a seasonal credit facility with National Australia Bank Ltd ("NAB"). The current facility, referred to as the 2016 NAB Facilities, was amended as of March 30, 2017 and expires on March 30, 2019. As of ~~March~~December 31, 2017, AUD ~~$9,407,499~~$7,837,767 (USD ~~$7,190,622)~~$6,115,026) was outstanding under the 2016 NAB Facilities.

The 2016 NAB Facilities, as currently in effect, comprises two distinct facility lines: (i) an overdraft facility (the "Overdraft Facility"), having a credit limit of AUD $980,000 (USD ~~$749,063~~$764,596 at ~~March~~December 31, 2017) and a borrowing base facility (the "Borrowing Base Facility"), having a credit limit of AUD $12,000,000 (USD ~~$9,172,200~~$9,362,400 at ~~March~~December 31, 2017).

The Borrowing Base Facility permits SGI to borrow funds for periods of up to 180 days, at SGI's discretion, provided that the term is consistent with its trading terms. Interest for each drawdown is set at the time of the drawdown as follows: (i) for Australian dollar drawings, based on the Australian Trade Refinance Rate plus 1.5% per annum and (ii) for foreign currency drawings, based on the British Bankers' Association Interest Settlement Rate for the relevant foreign currency for the relevant period, or if such rate is not available, the rate reasonably determined by NAB to be the appropriate equivalent rate, plus 1.5% per annum. As of ~~March~~December 31, 2017, the Borrowing Base Facility accrued interest on Australian dollar drawings at approximately ~~4.90%~~5.07% calculated daily. The Borrowing Base Facility is secured by a lien on all the present and future rights, property and undertakings of SGI, the mortgage on SGI's Keith, South Australia property and the Company's corporate guarantee (up to a maximum of AUD $15,000,000).

The Overdraft Facility permits SGI to borrow funds on a revolving line of credit up to the credit limit. Interest accrues daily and is calculated by applying the daily interest rate to the balance owing at the end of the day and is payable monthly in arrears. As of ~~March~~December 31, 2017, the Overdraft Facility accrued interest at approximately 6.77% calculated daily.

For both the Overdraft Facility and the Borrowing Base Facility, interest is payable each month in arrears. In the event of a default, as defined in the NAB Facility Agreement, the principal balance due under the facilities will thereafter bear interest at an increased rate per annum above the interest rate that would otherwise have been in effect from time to time under the terms of each facility (i.e., the interest rate increases by 4.5% per annum under the Borrowing Base Facility and the Overdraft Facility rate increases to 13.92% per annum upon the occurrence of an event of default).

Both facilities constituting the 2016 NAB Facilities are secured by a fixed and floating lien over all the present and future rights, property and undertakings of SGI and are guaranteed by the Company as noted above. The 2016 NAB Facilities contain customary representations and warranties, affirmative and negative covenants and customary events of default that permit NAB to accelerate SGI's outstanding obligations, all as set forth in the NAB facility agreements. SGI was in compliance with all NAB debt covenants at ~~March~~December 31, 2017.

In January 2015, NAB and SGI entered into a new business markets - flexible rate loan (the "Keith Building Loan") in the amount of AUD $650,000 (USD ~~$496,828~~$507,130 at ~~March~~December 31, 2017). Since entering into the Keith Building Loan, the limit has been changed on ~~two~~three occasions, with the current limit being AUD ~~$750,000~~$675,000 (USD ~~$573,263~~$526,635 at ~~March~~December 31, 2017), and a separate machinery and equipment facility (the "Keith Machinery and Equipment Facility") has been added ~~of up to~~with the limit being changed on two occasions, the current limit being AUD ~~$1,200,000~~$702,779 (USD ~~$917,220~~$548,308) at ~~March~~December 31, ~~2017).~~2017. At ~~March~~December 31, 2017, the principal balance on the Keith Building Loan was AUD ~~$650,000~~$575,000 (USD ~~$496,828)~~$448,615) with unused availability of AUD $100,000 (USD ~~$76,436)~~$78,021). At ~~March~~December 31, 2017, the principal balance on the Keith Machinery and Equipment Facility was AUD ~~$746,183~~$674,132 (USD ~~$570,345)~~$525,957) with no unused ~~availability of AUD $271,851 (USD $207,789).~~availability. In February 2016, NAB and SGI also entered into a master asset finance facility (the "Master Assets ~~Facility)~~Facility"). At ~~March~~December 31, 2017, the principal balance on the Master Assets Facility was AUD ~~$176,165~~$304,493 (USD ~~$134,652)~~$237,566) with unused availability of AUD ~~$23,835~~$445,507 (USD ~~$18,218)~~$347,585). The Master Asset Facility has various maturity dates through 2021 and have interest rates ranging from ~~4.86%~~4.79% to 5.31%.

The Keith Building Loan and Keith Machinery and Equipment Facility are used for the construction of a building on SGI's Keith, South Australia property, purchase of adjoining land and for the machinery and equipment for use in the operations of the building. The Keith Building Loan matures on November 30, 2024. The interest rate on the Keith Building Loan varies from pricing period to pricing period (each such period approximately 30 days), based on the weighted average of a specified basket of interest rates ~~(5.96%~~(6.11% as of ~~March~~December 31, 2017). Interest is payable each month in arrears. The Keith Machinery and Equipment Facility bears interest, payable in arrears, based on the Australian Trade Refinance Rate quoted by NAB at the time of the drawdown, plus 2.9%. The Keith Credit Facilities contain customary representations and warranties, affirmative and negative covenants and customary events of default that permit NAB to accelerate SGI's outstanding obligations, all as set forth in the facility agreement. They are secured by a lien on all the present and future rights, property and undertakings of SGI, the Company's corporate guarantee and a mortgage on SGI's Keith, South Australia property.

The annual maturities of short-term and long-term debt ~~excluding convertible debt addressed in Note 7,~~ are as follows:

Fiscal Year		Amount		Amount

2017	$	39,601
2018		10,263,438	$	223,473
2019		252,059		572,693
2020		277,018		2,656,068
2021		203,360		10,150,465
2022				92,427
Thereafter		266,349		117,012
Total	$	11,301,825	$	13,812,138

On December 31, 2014, the Company consummated the sale of senior secured convertible debentures (the "Debentures") and common stock purchase warrants (the "Warrants") to various institutional investors ("Investors") pursuant to the terms of a securities purchase agreement among the Company and the Investors. At closing, the Company received $27,000,000 in gross proceeds. Offering expenses of $1,931,105 attributed to the Debentures were recorded as deferred financing fees and recorded as a debt discount and offering expenses of $424,113 attributed to the Warrants were expensed during the year ended June 30, 2015. The net proceeds were paid directly to DuPont Pioneer in partial consideration for the purchase of certain DuPont Pioneer assets, the closing for which also took place on December 31, 2014.

At the date of issuance, the Debentures were due and payable on November 30, 2017, unless earlier converted or redeemed. The Debentures bear interest on the aggregate unconverted and then outstanding principal amount at 8% per annum, payable in arrears monthly beginning February 2, 2015. Commencing on the occurrence of any Event of Default (as defined in the Debentures) that results in the eventual acceleration of the Debentures, the interest rate will increase to 18% per annum. The monthly interest is payable in cash, or in any combination of cash or shares of the Company's common stock at the Company's option, provided certain "equity conditions" defined in the Debentures are satisfied.

Beginning on July 1, 2015, the Company was required to make monthly payments of principal as well, payable in cash or any combination of cash or shares of its common stock at the Company's option, provided all of the applicable equity conditions are satisfied. The Debentures contain certain rights of acceleration and deferral at the holder's option in the event a principal payment is to be made in stock and contains certain limited acceleration rights of the Company, provided certain conditions are satisfied.

During Fiscal Year 2016, the Company accelerated three redemption payments totaling $2,830,049.

~~Total convertible debt outstanding, excluding debt addressed in Note 6, is presented on the consolidated balance sheet as follows:~~

~~As of March 31, 2017, the Debentures were fully retired and had no outstanding balance.~~

The Debentures were initially convertible, at the holder's option, into the Company's common stock at a conversion price of $5.00. Pursuant to the terms of the Debentures, the conversion price was reset to $4.63 on September 30, 2015.

During the ~~nine months~~year ended ~~March 31,~~June 30, 2017, certain holders of the Debentures converted an aggregate of $3,168,342 of principal and interest into 684,321 shares of the Company's common stock in accordance with the terms of the Debentures. Upon conversion, the Company recognized interest expense of $194,939 related to unamortized debt discount on the Debentures and incurred $7,070 of stock issuance costs.

As of June 30, 2017, the Debentures were fully retired and had no outstanding balance.

The Warrants entitle the holders to purchase, in the aggregate, 2,699,999 shares of the Company's common stock. The Warrants are exercisable through their expiration on June 30, 2020, unless earlier redeemed. The Warrants were initially exercisable at an exercise price equal to $5.00. On September 30, 2015, pursuant to the terms of the Warrants, the exercise price was reset to $4.63. In addition, if the Company issues or is deemed to have issued securities at a price lower than the then applicable exercise price during the three-year period ending December 31, 2017, the exercise price of the Warrants will adjust based on a weighted average anti-dilution formula ("down-round protection"). On November 24, 2015, the Company closed on a private placement transaction in which 1,180,722 common shares were sold at $4.15 per share. Pursuant to the down-round protection terms of the Warrants, the exercise price was adjusted to $4.59 on November 24, 2015. On February 29, 2016, the Company completed a rights offering and accompanying noteholders' participation rights offering in which an aggregate of 2,125,682 shares of common stock were sold at $4.15 per share, triggering an adjustment of the exercise price of the Warrants to $4.53. On July 19, 2017, the Company completed a private placement transaction in which an aggregate of 2,685,000 shares of common stock were sold at $4.00 per share, triggering an adjustment of the exercise price of the Warrants to $4.46. On December 22, 2017, the Company completed a rights offering and backstop commitment in which an aggregate of 3,500,000 shares of common stock were sold at $3.50 per share, triggering an adjustment of the exercise price of the Warrants to $4.32. The down-round protection provision of the warrants expired on December 31, 2017.

The Warrants may be exercised for cash, provided that, if there is no effective registration statement available registering the exercise of the Warrants, the Warrants may be exercised on a cashless basis. At any time that (i) all equity conditions set forth in the Warrants have been satisfied, and (ii) the closing sales price of the common stock equals or exceeds $12.00 for 15 consecutive trading days (subject to adjustment for stock splits, reverse stock splits and other similar recapitalization events), the Company may redeem all or any part of the Warrants then outstanding for cash in an amount equal to $0.25 per Warrant.

Due to the down-round price protection included in the terms of the Warrants, the Warrants are treated as a derivative liability in the consolidated balance sheet, measured at fair value and marked to market each reporting period until the earlier of the Warrants being fully exercised or December 31, 2017, when the down-round protection expires. The down-round price protection expired on December 31, 2017, accordingly, the fair value of the Warrants as of December 31, 2017 was reclassified to additional paid in capital within the equity section of the balance sheet. The initial fair value of the Warrants on December 31, 2014 was $4,862,000. At ~~March~~December 31, 2017 and June 30, ~~2016,~~2017, the fair value of the Warrants was estimated at ~~$3,512,700~~$2,405,300 and ~~$4,354,100,~~$2,836,600, respectively. The Warrants were valued at ~~March~~December 31, 2017 using the Monte Carlo simulation model, under the following assumptions: (i) remaining expected life of ~~3.25~~2.5 years, (ii) volatility of ~~46.5%~~39.0%, (iii) risk-free interest rate of 1.92% and (iv) dividend rate of zero. The aggregate fair value of the Warrants derived via the Monte Carlo analysis were also weighted by a prior third party market transaction and third party indications of fair value. The prior third party market transaction was provided a weighting of 10.0% while the third party indications of fair value were provided a 50% weighting in the fair value analysis.

The Warrants were valued at June 30, 2017 using the Monte Carlo simulation model, under the following assumptions: (i) remaining expected life of 3 years, (ii) volatility of 45.6%, (iii) risk-free interest rate of 1.54% and (iv) dividend rate of zero. The aggregate fair value of the Warrants derived via the Monte Carlo analysis were also weighted by a prior third party market transaction and third party indications of fair value. The prior third party market transaction was provided a weighting of 10.0% while the third party indications of fair value were provided a 50% weighting in the fair value analysis. The Warrants were valued at June 30, 2016 using the Monte Carlo simulation model, under the following assumptions: (i) remaining expected life of 4.0 years, (ii) volatility of 49.9%, (iii) risk-free interest rate of 0. 86% and (iv) dividend rate of zero. The aggregate fair value of the Warrants derived via the Monte Carlo analysis were also weighted by a prior third party market transaction. The prior third party market transaction was provided a weighting of 10.0% in the fair value analysis.

Of the $27,000,000 in principal amount of Debentures sold in December 2014, $22,138,000 of the initial proceeds was allocated to the Debentures. The required redemption contingent upon the real estate sale was determined to be an embedded derivative not clearly and closely related to the borrowing. As such, it was bifurcated and treated as a derivative liability, recorded initially at its fair value of $150,000, leaving an allocation to the host debt of $21,988,000. The difference between the initial amount allocated to the borrowing and the face value of the Debentures ~~is being~~was amortized over the term of the Debentures using the effective interest method. Debt issuance costs totaling $1,931,105 ~~are~~were also ~~being~~ amortized over the term of the Debentures using the effective interest method. In addition, the reduction in the conversion price of the Debentures as of September 30, 2015 resulted in a beneficial conversion feature of $871,862, which was recognized as additional debt discount and an increase to additional paid-in capital.

The following table summarizes the total warrants outstanding at ~~March~~December 31, 2017:

The following table summarizes the total warrants outstanding at June 30, ~~2016:~~2017:

											Exercise Price	Expiration	Outstanding as			Outstanding as
	Issue Date		Exercise Price Per Share	Expiration Date	Outstanding as of June 30, 2015	New Issuances	Expired	Outstanding as of June 30, 2016	Issue Date		Per Share	Date	of June 30, 2016	New Issuances	Expired	of June 30, 2017

Underwriter warrants	May 2012	$	6.88	Feb 2017	50,000	-	-	50,000	May 2012	$	6.88	Feb 2017	50,000	-	(50,000)	-
Warrants	Dec 2014	$	4.53	Jun 2020	2,699,999	-	-	2,699,999	Dec 2014	$	4.53	Jun 2020	2,699,999	-	-	2,699,999
					2,749,999	-	-	2,749,999					2,749,999	-	(50,000)	2,699,999

The warrants issued in December 2014 ~~are~~were subject to down-round price ~~protection.~~protection until December 31, 2017. See Note ~~7 under the heading "Warrants"~~6 for further discussion.

The Company's subsidiary, SGI, is exposed to foreign currency exchange rate fluctuations in the normal course of its business, which the Company manages through the use of foreign currency forward contracts. These foreign currency contracts are not designated as hedging instruments; accordingly, changes in the fair value are recorded in current period earnings. These foreign currency contracts had a notional value of ~~$9,244,230~~$4,340,928 at ~~March~~December 31, 2017 and their maturities range from ~~April~~January 2018 to ~~August 2017.~~June 2018.

The Company records an asset or liability on the consolidated balance sheet for the fair value of the foreign currency forward contracts. The foreign currency contract assets totaled ~~$173,192~~$68,172 at ~~March~~December 31, 2017 ~~compared to foreign currency contract assets of $49,808~~and $166,629 at June 30, ~~2016.~~2017. The Company recorded a ~~gain~~loss on foreign exchange contracts of ~~$360,216~~$61,560 and ~~$110,346,~~$249,728, which is reflected in cost of revenue, for the three months ended ~~March~~December 31, 2017 and 2016, respectively. The Company recorded a loss on foreign exchange contracts of ~~$212,859~~$100,864 and ~~$275,123,~~$147,356, which is reflected in cost of revenue for the ~~nine~~six months ended ~~March~~December 31, 2017 and 2016, respectively.

In the DuPont Pioneer Acquisition, DuPont Pioneer retained ownership of its GMO (genetically modified) alfalfa germplasm and related intellectual property assets, as well as the right to develop new GMO-traited alfalfa germplasm. The retained GMO germplasm assets incorporate certain GMO traits that are licensed to DuPont Pioneer from third parties (the "Third Party GMO Traits").

Pursuant to the terms of the Asset Purchase and Sale Agreement for the DuPont Pioneer Acquisition, as amended, if required third party consents ~~are~~were received prior to ~~November 30, 2017 and~~January 31, 2018 (and subject to the satisfaction of certain other conditions specified in the Asset Purchase and Sale ~~Agreement,~~Agreement), either the Company or DuPont Pioneer ~~has~~had the right to enter into (and require the other party to enter into) on ~~December 29, 2017~~February 28, 2018 (or such earlier date as the parties agree) a proposed form of asset purchase and sale agreement, as the same may be updated in accordance with the terms of the Asset Purchase and Sale Agreement, pursuant to which Company would acquire additional GMO germplasm varieties and other related assets from DuPont Pioneer for a purchase price of $7,000,000.

Although the third party has informed the Company and DuPont Pioneer that it intends to provide the Company with the necessary consents and agreements to enable completion of the transaction, the Company did not obtain final executed consents and agreements prior to January 31, 2018. The Company is continuing discussions with DuPont Pioneer and the third party to obtain final executed consents and agreements and to complete the acquisition of DuPont Pioneer's GMO alfalfa assets. However, DuPont Pioneer has informed the Company that it currently does not intend to extend the deadline to complete the transaction. As a result, the Company may never enter into the second asset purchase agreement or close the acquisition of DuPont Pioneer's GMO germplasm varieties and related assets, in which case the Company would not be obligated to pay DuPont Pioneer the $7,000,000 purchase price.

Unless and until the Company completes the transactions contemplated under the second asset purchase agreement with DuPont Pioneer, DuPont Pioneer may purchase certain GMO-traited varieties of alfalfa seed from third parties. In addition, if the Company does not complete the transactions contemplated under the second asset purchase agreement, its production agreement with DuPont Pioneer (relating to GMO-traited varieties) will terminate on February 28, 2018, DuPont Pioneer will be free to pursue alternative production arrangements for the GMO-traited varieties, and DuPont Pioneer's minimum purchase commitments to the Company under the distribution agreement will be materially reduced. Although the Company is pursuing discussions with DuPont Pioneer regarding the possibility of extending the production agreement, DuPont Pioneer has informed the Company that it currently does not intend to extend the term of the Production Agreement past February 28, 2018. The termination of the Company's production agreement with DuPont Pioneer or any material reduction in the compensation payable to the Company under the agreement will have a material adverse effect on the Company's results of operations starting with the Company's fiscal year 2019.

Based on information currently available, management is not aware of any other matters that would have a material adverse effect on the Company's financial condition, results of operations or cash flows.

Glen D. Bornt, a member of the Company's Board of Directors until January 9, 2018, is the founder and President of Imperial Valley Milling Co. ("IVM"). He is ~~its~~IVM's majority shareholder and a member of its Board of Directors. ~~Fred Fabre, the Company's Vice President of Sales and Marketing,~~Glen D. Bornt is also a ~~minority~~majority shareholder of ~~IVM.~~

Kongal Seeds Pty. Ltd. ("Kongal"). IVM had a 15-year supply agreement with IVS, and this agreement was assigned by IVS to the Company when it purchased the assets of IVS in October 2012. IVM contracts with alfalfa seed growers in California's Imperial Valley and sells its growers' seed to the Company pursuant to a supply agreement. Under the terms of the supply agreement, IVM's entire certified and uncertified alfalfa seed production must be offered and sold to the Company, and the Company has the exclusive option to purchase all or any portion of IVM's seed production. The Company paid ~~$8,232,216~~$1,997,256 to IVM during the ~~nine~~six months ended ~~March~~December 31, 2017. Amounts due to IVM totaled ~~$77,599~~$115,582 and ~~$396,027~~$326,941 at ~~March~~December 31, 2017 and June 30, ~~2016,~~2017, respectively. The Company paid $0 to Kongal during the six months ended December 31, 2017. Amounts due to Kongal totaled $1,582 and $4,753 at December 31, 2017 and June 30, 2017, respectively.

On July 19, 2017, the Company entered into a Securities Purchase Agreement with certain purchasers, including MFP Partners, L.P. ("MFP"), a stockholder of the Company, and certain entities related to Wynnefield Capital Management LLC (collectively, "Wynnefield"), pursuant to which MFP purchased approximately $3.7 million of shares of its common stock and Wynnefield purchased approximately $3.0 million of shares of its common stock. Each of MFP and Wynnefield is a beneficial owner of more than 5% of the Company's common stock. Alexander C. Matina, a member of the Company's Board, is Vice President, Investments of MFP.

On October 11, 2017, the Company entered into a Securities Purchase Agreement with Mark W. Wong, the Company's President and Chief Executive Officer, pursuant to which the Company sold and issued an aggregate of 75,000 shares of its Common Stock at a purchase price of $3.50 per share, for aggregate gross proceeds of $262,500.

On December 22, 2017, the Company completed the closing of its previously announced rights offering. At the closing, the Company sold and issued an aggregate of 2,594,923 shares of its Common Stock at a subscription price of $3.50 per share pursuant to the exercise of subscriptions and oversubscriptions in the rights offering from its existing stockholders. Pursuant to an Investment Agreement, dated October 3, 2017, between the Company and MFP, MFP agreed to purchase, at the subscription price, all of the shares not purchased in the Rights Offering (the "Backstop Commitment"). Accordingly, on December 22, 2017, the Company and MFP completed the closing of the Backstop Commitment, in which the Company sold and issued 905,077 shares of its Common Stock to MFP. Combined, the Company sold and issued an aggregate of 3,500,000 shares of its common stock for aggregate gross proceeds of $12.25 million.

In October 2009 and January 2010, the Company's Board of Directors and stockholders, respectively, approved the 2009 Equity Incentive Plan (as amended and/or restated from time to time, the "2009 Plan"). The plan authorized the grant and issuance of options, restricted shares and other equity compensation to the Company's directors, employees, officers and consultants, and those of the Company's subsidiaries and parent, if any. In October 2012 and December 2012, the Company's Board of Directors and stockholders, respectively, approved the amendment and restatement of the 2009 Plan, including an increase in the number of shares available for issuance as grants and awards under the Plan to 1,250,000 shares. In September 2013 and December 2013, the Company's Board of Directors and stockholders, respectively, approved the amendment and restatement of the 2009 Plan, including an increase in the number of shares available for issuance as grants and awards under the Plan to 1,700,000 shares. In September 2015 and December 2015, the Company's Board of Directors and stockholders, respectively, approved the amendment and restatement of the 2009 Plan, including an increase in the number of shares available for issuance as grants and awards under the Plan to 2,450,000 shares.

The term of incentive stock options granted under the 2009 Plan may not exceed ten years, or five years for incentive stock options granted to an optionee owning more than 10% of the Company's voting stock. The exercise price of options granted under the 2009 Plan must be equal to or greater than the fair market value of the shares of the common stock on the date the option is granted. An incentive stock option granted to an optionee owning more than 10% of voting stock must have an exercise price equal to or greater than 110% of the fair market value of the common stock on the date the option is granted.

The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. Stock options issued to non-employees are accounted for at their estimated fair value. The fair value of options granted to non-employees is re-measured as they vest. The Company amortizes stock-based compensation expense on a straight-line basis over the requisite service period.

The Company utilizes a Black-Scholes-Merton option pricing model, which includes assumptions regarding the risk-free interest rate, dividend yield, life of the award, and the volatility of the Company's common stock to estimate the fair value of employee options grants.

Weighted average assumptions used in the Black-Scholes-Merton model are set forth below:

	March 31,	June 30,	December 31,
	2017	2016	2017	2016

Risk free rate	1.2% - 1.9%	1.5% - 1.6%	1.72% - 1.91%	1.2% - 1.9%
Dividend yield	0%	0%	0%	0%
Volatility	39.2% - 51.6%	50.4% - 50.8%	45.3% - 45.5%	39.2% - 51.6%
Average forfeiture assumptions	2.4%	6.1%	1.4%	2.4%

During the ~~nine~~six months ended ~~March~~December 31, 2017, the Company granted ~~80,610~~62,755 options to ~~its directors~~certain members of the executive management team and ~~officers~~other employees at exercise prices ranging from ~~$4.75 - $4.86.~~$3.00 to $3.10. These options vest in either quarterly or annual periods ~~ranging from one year annually to quarterly~~ over three years, and expire ten years from the date of grant.

A summary of stock option activity for the ~~nine~~six months ended ~~March~~December 31, 2017 and year ended June 30, ~~2016~~2017 is presented below:

				Weighted -						Weighted-
			Weighted -	Average					Weighted -	Average
			Average	Remaining		Aggregate			Average	Remaining		Aggregate
	Number		Exercise Price	Contractual		Intrinsic	Number		Exercise Price	Contractual		Intrinsic
	Outstanding		Per Share	Life (Years)		Value	Outstanding		Per Share	Life (Years)		Value
Outstanding at June 30, 2015	901,697	$	5.33	4.1	$	392,850
Granted	203,500		4.56	9.7		-
Exercised	(14,582)		3.95	-		-
Canceled/forfeited/expired	(69,197)		6.08	-		-
Outstanding at June 30, 2016	1,021,418		5.14	4.2		142,381	1,021,418	$	5.14	4.2		142,381
Granted	80,610		4.81	-		-	230,610		4.19	-		-
Exercised	(232,000)		4.20	-		-	(232,000)		4.20	-		-
Canceled/forfeited/expired	(29,500)		5.95	-		-	(29,500)		5.95	-		-
Outstanding at March 31, 2017	840,528		5.34	4.7		293,619
Options vested and exercisable at March 31, 2017	650,694		5.57	4.2		218,448
Options vested and expected to vest as of March 31, 2017	840,180	$	5.34	4.7	$	293,493
Outstanding at June 30, 2017							990,528		5.12	4.3		100,344
Granted							62,755		3.08	-		-
Exercised							-		-	-		-
Canceled/forfeited/expired							(190,000)		6.99	-		-
Outstanding at December 31, 2017							863,283		4.56	6.5		72,914
Options vested and exercisable at December 31, 2017							632,416		4.82	5.6		19,183
Options vested and expected to vest as of December 31, 2017							862,808	$	4.56	6.5	$	72,496

The weighted average grant date fair value of options granted and outstanding at ~~March~~December 31, 2017 was ~~$1.45.~~$1.58. At ~~March~~December 31, 2017, the Company had ~~$298,860~~$302,942 of unrecognized stock compensation expense, net of estimated forfeitures, related to the options under the 2009 Plan, which will be recognized over the weighted average remaining service period of ~~1.4~~2.23 years. The Company settles employee stock option exercises with newly issued shares of common stock.

On July 15, 2015, the Company issued 88,333 restricted stock units to certain members of the executive management team. The restricted stock units have varying vesting periods whereby 13,250 restricted stock units vest on October 1, 2015 and the remaining 75,083 restricted stock units vest quarterly in equal installments over a three-year period, commencing on July 1, 2015. The fair value of the award was $420,465 and was based on the closing stock price on the date of grant.

On December 11, 2015, the Company issued 28,059 restricted stock units to certain members of the executive management team and other employees. The restricted stock units have varying vesting periods whereby 500 restricted stock units vest on December 11, 2015, 4,259 restricted stock units vest in quarterly installments over a one-year period, and the remaining 23,300 restricted stock units vest annually in equal installments over a three-year period. The fair value of the award was $119,251 and was based on the closing stock price on the date of grant.

On March 18, 2016, the Company issued 3,000 restricted stock units. The restricted stock units have varying vesting periods whereby 1,000 restricted stock units vested on March 18, 2016; and the remaining 2,000 restricted stock units vest annually in equal installments over a three-year period. The fair value of the award was $12,180 and was based on the closing stock price on the date of grant.

During the ~~nine months~~year ended ~~March 31,~~June 30, 2017, the Company issued ~~76,085~~77,275 restricted stock units to its directors, certain members of the executive management team, and other employees. The restricted stock units have varying vesting periods ranging from immediate vesting to annual installments over a three-year period. The fair value of the awards totaled ~~$369,531~~$374,530 and was based on the closing stock price on the date of grants.

During the six months ended December 31, 2017, the Company issued 38,114 restricted stock units to its certain members of the executive management team and other employees. The restricted stock units vest in either quarterly or annual periods and vest over three-years. The fair value of the awards totaled $116,486 and was based on the closing stock price on the date of grants.

The Company recorded ~~$239,579~~$311,067 and ~~$192,719~~$240,241 of stock-based compensation expense associated with grants of restricted stock units during the ~~three~~six months ended March 31, 2017 and 2016, respectively. The Company recorded $674,076 and $586,564 of stock-based compensation expense associated with grants of restricted stock units during the nine months ended MarchDecember 31, 2017 and 2016, respectively. A summary of activity related to non-vested restricted stock units is presented below:

Nine Months Ended March 31, 2017
Six Months Ended December 31, 2017					Six Months Ended December 31, 2017
				Weighted -				Weighted -
	Number of		Weighted -	Average	Number of		Weighted-	Average
	Nonvested		Average	Remaining	Nonvested		Average	Remaining
	Restricted		Grant Date	Contractual	Restricted		Grant Date	Contractual
	Stock Units		Fair Value	Life (Years)	Stock Units		Fair Value	Life (Years)
Beginning nonvested restricted units outstanding	170,879	$	7.51	1.5	120,971	$	5.59	1.5
Granted	76,085		4.86	1.7	38,114		3.06	1.7
Vested	(79,700)		7.75	-	(90,066)		5.68	-
Forfeited	-		-	-	(3,680)		-	-
Ending nonvested restricted units outstanding	167,264	$	6.19	1.1	65,339	$	4.06	1.6

At ~~March~~December 31, 2017, the Company had ~~$777,295~~$220,169 of unrecognized stock compensation expense related to the restricted stock units, which will be recognized over the weighted average remaining service period of ~~1.1~~1.6 years.

At ~~March~~December 31, 2017, there were ~~705,914~~526,603 shares available under the 2009 Plan for future grants and awards.

Stock-based compensation expense recorded for stock options, restricted stock grants and restricted stock units for the three months ended ~~March~~December 31, 2017 and 2016, totaled ~~$306,800~~$193,571 and ~~$289,314,~~$296,235, respectively. ~~Stock- based~~Stock-based compensation expense recorded for stock options, restricted stock grants and restricted stock units for the ~~nine~~six months ended ~~March~~December 31, 2017 and 2016, totaled ~~$885,459~~$451,033 and ~~$917,489,~~$578,659, respectively.

The below table represents supplemental information to the Company's consolidated statements of cash flows for non-cash activities during the ~~nine~~six months ended ~~March~~December 31, 2017 and 2016, respectively.

You should read the following discussion of our financial condition and results of operations in conjunction with our consolidated financial statements and the related notes included in Part I, Item 1, "Financial Statements" of this Quarterly Report on Form 10-Q. In addition to our historical consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements as referred to on page 12 of this Quarterly Report on Form 10-Q. Factors that could cause or contribute to these differences include those discussed in our Annual Report on Form 10-K for the fiscal year ended June 30, ~~2016,~~2017, particularly in Part I, Item 1A, "Risk Factors."

Founded in 1980 and headquartered in ~~the Central Valley of~~Sacramento, California, we are a global agricultural company. Grounded in our historical expertise and what we believe is our present leading position in the breeding, production and sale of alfalfa seed, we continue to build towards our goal of being recognized as the world's preferred proprietary forage, grain and specialty crop seed company. In addition to our primary activities in alfalfa seed, we have recently expanded our product portfolio by adding hybrid sorghum and sunflower seed, which complement our alfalfa seed offerings by allowing us to leverage our infrastructure, research and development expertise and our distribution channels, as we begin to diversify into what we believe are higher margin opportunities. We also continue to conduct our stevia breeding program, having ~~filed two~~three patents granted and one additional patent ~~applications in fiscal 2016.~~application pending.

Following our initial public offering in fiscal year 2010, we expanded certain pre-existing business initiatives and added new ones, including:

We have accomplished these expansion initiatives through a combination of organic growth and strategic acquisitions, foremost among them:

We believe our 2013 combination with SGI created the world's largest non-dormant alfalfa seed company and gave us the competitive advantages of year-round production in that market. With the completion of the acquisition of dormant alfalfa seed assets from DuPont Pioneer in December 2014, we believe we have become the largest alfalfa seed company worldwide (by volume), with industry-leading research and development, as well as production and distribution capabilities in both hemispheres and the ability to supply proprietary dormant and non-dormant alfalfa seed. Our operations span the world's alfalfa seed production regions, with operations in the San Joaquin and Imperial Valleys of California, five additional Western states, Australia and three provinces in Canada.

Our May 2016 acquisition of the hybrid sorghum and sunflower germplasm business and assets of SV Genetics signals management's commitment to our strategy of identifying opportunities to diversify our product lines and improve our gross margins.

We derive most of our revenue from the sale of our proprietary alfalfa seed varieties. We expect that over the next several years, a substantial majority of our revenue will continue to be generated from the sale of alfalfa seed, although we are continually assessing other possible product offerings or means to increase revenue, including expanding into other, higher margin crops. In late fiscal year 2016, we began that expansion with the acquisition of the hybrid sorghum and sunflower business and assets of SV Genetics. Revenue from the newly-acquired SV Genetics germplasm will be primarily derived from the sale of sorghum and sunflower seed as well as royalty-based payments set forth in various licensing agreements.

Fiscal year 2016 was the first full fiscal year in which we had a full range of non-dormant and dormant alfalfa seed varieties. This is expected to enable us to significantly expand the geographic reach of our sales efforts. The mix of our product offerings will continue to change over time with the introduction of new alfalfa seed varieties resulting from our robust research and development efforts, including our potential expansion into ~~genetically- modified~~genetically-modified varieties in future periods. Currently, we have a long-term distribution agreement with DuPont Pioneer, which we expect will be the source of a significant portion of our annual revenue through December 2024.

Our revenue will fluctuate depending on the timing of orders from our customers and distributors. Because some of our large customers and distributors order in bulk only one or two times per year, our product revenue may fluctuate significantly from period to period. However, some of this fluctuation is offset by having operations in both the northern and southern hemispheres.

Our stevia breeding program has yet to generate any meaningful revenue. However, management continues to evaluate this portion of our business and assess various means to monetize the results of our effort to breed new, better tasting stevia varieties. Such potential opportunities include possible licensing agreements and royalty-based agreements.

Cost of revenue relates to sale of our seed varieties and consists of the cost of procuring seed, plant conditioning and packaging costs, direct labor and raw materials and overhead costs.

Seed and stevia research and development expenses consist of costs incurred in the discovery, development, breeding and testing of new products incorporating the traits we have specifically selected. These expenses consist primarily of employee salaries and benefits, consultant services, land leased for field trials, chemicals and supplies and other external expenses. With the acquisition of SV Genetics in late fiscal 2016, similar costs are now being incurred as we continue the research and development efforts begun by SV Genetics in the development of new varieties of hybrid sorghum and sunflower seed germplasm. Because we have been in the alfalfa seed breeding business since our inception in 1980, we have expended far more resources in development of our proprietary alfalfa seed varieties throughout our history than on our stevia breeding program, which we commenced in fiscal year 2010.

In fiscal year 2013, we made the decision to shift the focus of our stevia program away from commercial production and towards the breeding of improved varieties of stevia. We have continued that effort, which has resulted in the granting by the USPTO of ~~two~~three patents covering stevia plant varieties SW 107, SW 201 and SW ~~201.~~129. Additionally, we have applied for patent protection with the ~~U.S. Patent and Trademark Office~~USPTO for SW 227 for the fresh and dry leaf ~~market, and SW 129 for the commercial processing~~ market.

Our research and development expenses increased significantly with the acquisition of the alfalfa research and development assets of DuPont Pioneer in December 2014. We also have expanded our genetics research both internally and in collaboration with third parties. In addition, we acquired additional research and development operations in connection with our May 2016 acquisition of SV Genetics that we expect will factor into an overall increase in R&D expense. Overall, we have been focused on reducing research and development expense, while balancing that objective against the recognition that continued advancement in product development is an important part of our strategic planning. We expect our research and development expenses will fluctuate from period to period as a result of the timing of various research and development projects.

Our internal research and development costs are expensed as incurred, while third party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. The costs associated with equipment or facilities acquired or construed for research and development activities that have alternative future uses are capitalized and depreciated on a straight-line basis over the estimated useful life of the asset.

Selling, general, and administrative expenses consist primarily of employee costs, including salaries, employee benefits and share-based compensation, as well as professional service fees, insurance, marketing, travel and entertainment expense, public company expense and other overhead costs. We proactively take steps on an ongoing basis to control selling, general and administrative expense as much as is reasonably possible.

Most of the depreciation and amortization expense on our statement of operations consists of amortization expense. We amortize intangible assets, including those acquired from DuPont Pioneer in December 2014 and from SV Genetics in May 2016, using the straight-line method over the estimated useful life of the asset, consisting of periods of 10-30 years for technology/IP/germplasm, 20 years for customer relationships and trade names and 2-20 years for other intangible assets. Property, plant and equipment is depreciated using the straight-line method over the estimated useful life of the asset, consisting of periods of ~~15-28~~5-28 years for buildings, 3-20 years for machinery and equipment and 3-5 years for vehicles.

Other expense consists primarily of foreign currency gains and losses, changes in the fair value of derivative liabilities related to our warrants, changes in the fair value of our contingent consideration obligations and interest expense in connection with amortization of debt discount. In addition, interest expense consists of interest costs related to outstanding borrowings on our credit facilities, including our current KeyBank revolving line of credit and on SGI's credit facilities in South Australia, our 8% senior secured convertible debentures that were issued in December 2014 ~~and~~which were fully paid off on March 1, 2017, our three-year secured promissory note issued in December 2014 in connection with the DuPont Pioneer acquisition which was paid off on December 1, 2017, and our ~~five-year subordinated~~newly issued secured promissory ~~note that matures in October 2017 that was issued in connection~~notes with ~~the IVS acquisition.~~Conterra.

Our effective tax rate is based on income, statutory tax rates, differences in the deductibility of certain expenses and inclusion of certain income items between financial statement and tax return purposes, and tax planning opportunities available to us in the various jurisdictions in which we operate. Under U.S. GAAP, if we determine that a tax position is more likely than not of being sustained upon audit, based solely on the technical merits of the position, we recognize the benefit. Tax regulations require certain items to be included in the tax return at different times than when those items are required to be recorded in the consolidated financial statements. As a result, our effective tax rate reflected in our consolidated financial statements is different ~~than~~from that reported in our tax returns. Some of these differences are permanent, such as meals and entertainment expenses that are not fully deductible on our tax return, and some are temporary differences, such as depreciation expense. Temporary differences create deferred tax assets and liabilities. Deferred tax assets generally represent items that can be used as a tax deduction or credit in our tax return in future years for which we have already recorded the tax benefit in our consolidated statements of operations. In the fourth quarter of fiscal year 2017, we recorded a valuation allowance against all of our deferred tax assets. The full valuation allowance was recorded during the fiscal year 2017 as a result of changes to our operating results and future projections, resulting from a recent decline in export sales to Saudi Arabia. In addition, our available tax planning strategies are currently not expected to overcome the uncertainty of the Saudi Arabian market. As a result of these factors, we don't believe that it is more likely than not that our deferred tax assets will be realized.

Three Months Ended ~~March~~December 31, 2017 Compared to the Three Months Ended ~~March~~December 31, 2016

Revenue for three months ended ~~March~~December 31, 2017 was ~~$21,012,243~~$20,532,796 compared to ~~$25,013,779~~$24,225,744 for the three months ended ~~March~~December 31, 2016. ~~Revenue~~The $3,692,948 decrease in revenue for the ~~third quarter~~three months ended December 31, 2017 was primarily due to a decrease of ~~fiscal 2017 decreased $4,001,536~~sales to the Saudi Arabia markets of approximately $1.3 million. Regulatory uncertainty in Saudi Arabia surrounding water use restrictions for large forage producers caused customers in the region to defer purchases and/or reduce inventory carrying levels. The outlook for demand for our non-dormant varieties in Saudi Arabia over the next two to four years continues to be uncertain because of the potential for water use restrictions and further regulations from the ~~comparable period~~Saudi Arabian government on water usage. If there is a significant decrease in demand from our customers in Saudi Arabia, we would experience a material decline in revenue and earnings in the ~~prior year.~~absence of growth in other regions and other products.

Sales into international markets represented 23% and 30% of revenue during the three months ended December 31, 2017 and 2016, respectively. Domestic revenue accounted for 77% and 70% of our total revenue for the three months ended December 31, 2017 and 2016, respectively. The increase in domestic revenue as a percentage of total revenue is primarily attributed to timing differences in shipments to our largest customer.

We recorded sales of approximately ~~$16.2~~$15.3 million from our distribution and production agreements with DuPont Pioneer during the three months ended ~~March~~December 31, 2017, which was ~~relatively consistent with~~a decrease of $0.8 million from the prior ~~period~~year amount of $16.1 million. The decrease in revenue for the third quarter of fiscal 2017 was primarily due to a decrease in our export business due to delayed shipments into Saudi Arabia. Recent regulatory uncertainty in Saudi Arabia surrounding water use restrictions for large forage producers is causing certain customers in the region to defer purchases and/or reduce inventory carrying levels in the near-term. Based on information currently available to management, we believe that such regulatory uncertainty will be resolved or clarified in the coming months.

Sales to international customers (by destination country) represented 20% and 34% of revenue during the three months ended March 31, 2017 and 2017, respectively. Domestic revenue accounted for 80% and 66% of our total revenue for the three months ended March 31, 2017 and 2016, respectively. The increase in domestic revenue as a percentage of revenue is directly attributed to an increase in sales concentration to DuPont Pioneer during the third quarter. We expect DuPont Pioneer to represent a significant portion of our domestic sales, as well as overall sales, for the foreseeable future.

Cost of revenue of ~~$15,208,896~~$15,860,629 for the three months ended ~~March~~December 31, 2017 was ~~72.4%~~77.2% of revenue, while the cost of revenue of ~~$19,500,605~~$19,005,270 for the three months ended ~~March~~December 31, 2016 was ~~78.0%~~78.5% of revenue. Cost of revenue decreased on a dollar basis primarily due to the decrease in revenue as well as a reduction of product costs.

Total gross profit margin for the three months ended ~~March~~December 31, 2017 was ~~27.6%~~22.8% compared to ~~22.0%~~21.5% in the ~~third quarter~~comparable period of ~~fiscal 2016.~~the prior year. The increase in gross profit margins was primarily due to product sales mix during the ~~quarter~~current period where we had a higher concentration of sales, as a percentage of total revenue, to DuPont Pioneer which are higher margin sales. Additionally, the product costs of proprietary seed are lower in the current year due to more favorable production contracts and arrangements.

While there will continue to be quarterly fluctuations in gross profit margin based on product sales mix, we anticipate improved gross margins in fiscal 2018 as a result of a number of initiatives we are deploying.

Selling, General and Administrative ("SG&A") expense for the three months ended ~~March~~December 31, 2017 totaled ~~$2,720,131~~$2,446,955 compared to ~~$2,459,737~~$2,592,059 for the three months ended ~~March~~December 31, 2016. The ~~$260,394 increase~~$145,104 decrease in SG&A expense versus the ~~third~~second quarter of the prior year was primarily due to ~~bad debt expense~~cost reduction initiatives coupled with a decrease in stock based compensation of ~~$100,000, an increase in professional fees and personnel and related costs to accommodate the anticipated growth in operations.~~$102,664. As a percentage of revenue, SG&A expenses were ~~12.9%~~11.9% in the current quarter compared to ~~9.8%~~10.7% in the ~~third quarter of the prior year.~~three months ended December 31, 2016.

Research and development expenses for the three months ended ~~March~~December 31, 2017 totaled ~~$714,512~~$855,164 compared to ~~$626,316~~$748,571 for the three months ended ~~March~~December 31, 2016. The $106,593 increase ~~of $88,196~~ in ~~the third quarter of fiscal 2017 was primarily~~research and development expense is driven by additional investment in our hybrid sorghum and sunflower programs. We expect our research and development ~~activities in connection with the recent SVG Acquisition partially offset by reductions in the stevia and alfalfa programs.~~spend for fiscal 2018 to total approximately $3.4 million.

Depreciation and amortization expense for the three months ended ~~March~~December 31, 2017 was ~~$798,559~~$870,981 compared to ~~$796,062~~$842,454 for the three months ended ~~March~~December 31, 2016. Included in the amount was amortization expense for intangible assets, which totaled $555,471 in the three months ended December 31, 2017 and $555,977 in the three months ended ~~March~~December 31, ~~2017~~2016. The $28,527 increase in depreciation and ~~$558,358 in~~amortization expense over the ~~three months ended March 31, 2016.~~comparable period of the prior year is primarily driven by additional depreciation expense associated with fixed asset additions.

During the nine months ended March 31, 2017, we recorded an impairment charge of $319,001. The impairment charge related to the carrying value of certain stand establishment assets which were deemed impaired and uncollectible from a certain sub-leasee.

We incurred a foreign currency loss of ~~$2,125~~$7,472 for the three months ended ~~March~~December 31, 2017 compared to a ~~loss~~gain of ~~$87,342~~$2,837 for the three months ended ~~March~~December 31, 2016. The foreign currency gains and losses are associated with SGI, our wholly-owned subsidiary in Australia.

The derivative warrant liability iswas considered a level 3 fair value financial instrument and iswas measured at each reporting period until December 31, 2017 at which time the warrants were reclassified to equity due to the expiration of the down-round price protection provision. We recorded a non-cash change in derivative warrant liability loss of $341,199 in the three months ended December 31, 2017 compared to a gain of $959,200 in the three months ended December 31, 2016. The loss represents the increase in fair value of the outstanding warrants issued in December 2014.

The contingent consideration obligations are considered level 3 fair value financial instruments and will be measured at each reporting period. The $0 and $57,282 charges to non-cash change in contingent consideration obligations expense for the three months ended December 31, 2017 and 2016, respectively; represents the increase in the estimated fair value of the contingent consideration obligations during that respective period due to the decrease in the present value discount factor used to estimate the fair value of the contingent consideration obligations. The earn-out payment to DuPont Pioneer was finalized in the amount of $2,500,000 and this was added to the Pioneer Note in October 2017.

Non-cash amortization of debt discount expense for the three months ended December 31, 2017 was $33,100 compared to $381,660 for the three months ended December 31, 2016. The expense in the current quarter represents the amortization of the debt issuance costs associated with our KeyBank working capital facility and our secured property and equipment notes with Conterra. The expense in the prior year represents the amortization of the debt discount, beneficial conversion feature and debt issuance costs associated with the convertible debentures issued December 31, 2014 and the debt issuance costs associated with our KeyBank working capital facility. As of March 1, 2017, the convertible debentures have been fully retired and accordingly, the amortization of debt discount associated with the convertible debentures is complete.

Interest expense during the three months ended December 31, 2017 totaled $383,894 compared to $295,042 for the three months ended December 31, 2016. Interest expense for the three months ended December 31, 2017 primarily consisted of interest incurred on the note payable issued to DuPont Pioneer as part of the purchase consideration for the DuPont Pioneer acquisition, the working capital credit facilities with KeyBank and NAB, and the new secured property and equipment loans entered into in November 2017. Interest expense for the three months ended December 31, 2016 primarily consisted of interest incurred on the convertible debentures issued on December 31, 2014, on the note payable issued to DuPont Pioneer as part of the purchase consideration for the DuPont Pioneer acquisition and the working capital credit facilities with KeyBank and NAB. The $88,852 increase in interest expense for the three months ended December 31, 2017 is primarily driven by $91,363 of interest on the new secured property and equipment loans.

Income tax expense totaled $148,702 for the three months ended December 31, 2017 compared to an income tax expense of $106,485 for the three months ended December 31, 2016. Our effective tax rate expense was (59.1%) for the three months ended December 31, 2017 compared to 8.4% for the three months ended December 31, 2016. The decrease in our effective tax rate for the three months ended December 31, 2017 is attributable to the full valuation allowance established against our deferred tax assets which was recorded during the fourth quarter of fiscal 2017. Due to the valuation allowance, we do not record the income tax expense or benefit related to substantially all of our current year operating results, as such results are generally incorporated in our net operating loss deferred tax asset position, which has a full valuation allowance against it. However, we did record tax expense related to certain other factors occurring throughout the year. For example, we have certain intangible assets with indefinite lives for financial reporting purposes. The write down of these assets cannot be assumed and thus, the deferred tax liability created by the difference in the basis in these assets for financial reporting and tax purposes cannot be used as a source of taxable income against our deferred tax assets. The increase in the deferred tax liability due the yearly tax amortization on these intangible assets is recorded as income tax expense. We also analyzed additional information on our tax return filings in the second quarter of fiscal 2018. To the extent that differences arise from the estimates of tax return filings, these differences are generally recorded in the quarter that they arise and are commonly referred to as provision to return adjustments. Such adjustments related to our Australian tax return filings also generated additional income tax expense for the quarter ended December 31, 2017.

On December 22, 2017, President Trump signed into law the Tax Cuts and Jobs Act (the "Tax Act"). The Tax Act reduced the corporate tax rate from the maximum federal statutory rate of 35% to 21%. The Tax Act states that the 21% corporate tax rate is effective for tax years beginning on or after January 1, 2018. However, existing tax law, which was not amended under the Tax Act, governs when a change in tax rate is effective. Existing tax law provides that if the taxable year includes the effective date of any rate change (unless the change is the first date of the taxable year), taxes should be calculated by applying a blended rate to the taxable income for the year. Our blended federal rate is 27.6%. As a result of the new law, we have concluded that our deferred tax assets will need to be revalued. Our deferred tax assets represent a reduction in corporate taxes that are expected to be paid in the future. As a result of the Tax Act, we have estimated a reduction to the value of our deferred tax assets which is almost entirely offset by a reduction to our valuation allowance in the second quarter of the year ending June 30, 2018. The net impact of the decrease to both the deferred tax assets and the valuation allowance will be a remeasuring of our net deferred tax liability associated with indefinite lived intangibles for which we cannot predict a reversal into taxable income. In conjunction with the tax law changes, the SEC staff issued Staff Accounting Bulletin No. 118 ("SAB 118") to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations)

in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. We have recognized the provisional tax impacts related to deemed repatriated earnings, the potential impact of new section 162(m) rules on our deferred tax balances, and the revaluation of deferred tax assets and liabilities and included these amounts in our consolidated financial statements for the quarter ended December 31, 2017. The ultimate impact, which is expected to be recorded by June 30, 2018, may differ from these provisional amounts, possibly materially, due to, among other things, additional analysis, changes in interpretations and assumptions we have made, additional regulatory guidance that may be issued, and actions we may take as a result of the Tax Act, and the fact that we cannot definitively predict what our deferred tax balance will ultimately be as of June 30, 2018. The Tax Act allows for one hundred percent expensing of the cost of qualified property acquired and placed in service after September 27, 2017 and before January 1, 2023. We do not plan to take advantage of this provision for the near term and have the option of opting out of this provision. In addition, net operating losses incurred in tax years beginning after December 31, 2017 are only allowed to offset a taxpayer's taxable income by eighty percent, but those net operating losses are allowed to be carried forward indefinitely with no expiration. Also as part of the Tax Act, our net interest expense deductions are limited to 30% of earnings before interest, taxes, depreciation, and amortization through 2021 and of earnings before interest and taxes thereafter. This provision also takes effect for tax years beginning after 2017 and isn't expected to have a material impact to our deferred tax asset position. The Tax Act also incorporates changes to certain international tax provisions. There is a one-time transition tax on foreign income earned by subsidiaries at a rate of 15.5% for cash and cash equivalents and at a rate of 8% for the remainder of the foreign earnings. There is a provision for the current inclusion in US taxable income of global intangible low-tax income and also the imposition of a tax equal to its base erosion minimum tax amount. The new laws incorporate a potential benefit for foreign derived intangible income, but the benefit only applies if the foreign derived sales and services income exceeds a calculated 'routine return' and if we have taxable income. We do not currently anticipate that any of the foreign provisions will have an impact to our tax accounts.

Six Months Ended December 31, 2017 Compared to the Six Months Ended December 31, 2016

Revenue for six months ended December 31, 2017 was $31,244,512 compared to $36,475,317 for the six months ended December 31, 2016. The $5,230,805 decrease in revenue for the six months ended December 31, 2017 was primarily due to a decrease of sales to the Saudi Arabia markets of approximately $4.4 million. Regulatory uncertainty in Saudi Arabia surrounding water use restrictions for large forage producers caused customers in the region to defer purchases and/or reduce inventory carrying levels. The outlook for demand for our non-dormant varieties in Saudi Arabia over the next two to four years continues to be uncertain because of the potential for water use restrictions and further regulations from the Saudi Arabian government on water usage. If there is a significant decrease in demand from our customers in Saudi Arabia, we would experience a material decline in revenue and earnings in the absence of growth in other regions and other products. The decrease in revenue directed to the Saudi Arabia markets was partially offset by an increase in sales to the domestic market and Argentina.

Sales into international markets represented 38% and 46% of revenue during the six months ended December 31, 2017 and 2016, respectively. Domestic revenue accounted for 62% and 54% of our total revenue for the six months ended December 31, 2017 and 2016, respectively. The increase in domestic revenue as a percentage of total revenue is directly attributable to reduced sales to customers in Saudi Arabia.

We recorded sales of approximately $18.1 million from our distribution and production agreements with DuPont Pioneer during the six months ended December 31, 2017, which was an increase of $0.5 million from the prior year amount of $17.6 million. We expect DuPont Pioneer to represent a significant portion of our domestic sales, as well as overall sales, for the foreseeable future.

Cost of revenue of $24,236,757 for the six months ended December 31, 2017 was 77.6% of revenue, while the cost of revenue of $29,311,580 for the six months ended December 31, 2016 was 80.4% of revenue. Cost of revenue decreased on a dollar basis primarily due to the decrease in revenue.

Total gross profit margin for the six months ended December 31, 2017 was 22.4% compared to 19.6% in the comparable period of the prior year. The increase in gross profit margins was primarily attributable to decreases in cost of goods sold compared to the prior year for S&W's non-dormant varieties. The product costs of proprietary seed are lower in the current year due to more favorable production contracts and arrangements.

Selling, General and Administrative ("SG&A") expense for the six months ended December 31, 2017 totaled $5,361,035 compared to $5,047,263 for the six months ended December 31, 2016. The $313,772 increase in SG&A expense versus the comparable period of the prior year was primarily due to an increase in sales personnel and related costs, as well as an increase in consulting fees of approximately $190,000. As a percentage of revenue, SG&A expenses were 17.2% in the six months ended December 31, 2017, compared to 13.8% in the six months ended December 31, 2016.

Research and development expenses for the six months ended December 31, 2017 totaled $1,597,081 compared to $1,490,113 for the six months ended December 31, 2016. The $106,968 increase in research and development expense versus the second quarter of the prior year is driven by additional investment in our hybrid sorghum and sunflower programs. We expect our research and development spend for fiscal 2018 to total approximately $3.4 million.

Depreciation and amortization expense for the six months ended December 31, 2017 was $1,759,233 compared to $1,677,151 for the six months ended December 31, 2016. Included in the amount was amortization expense for intangible assets, which totaled $1,128,392 for the six months ended December 31, 2017 and $1,111,954 for the six months ended December 31, 2016. The $82,082 increase in depreciation and amortization expense over the comparable period of the prior year is primarily driven by additional depreciation expense associated with fixed asset additions.

We incurred a foreign currency loss of $22,030 for the six months ended December 31, 2017 compared to a gain of $6,483 for the six months ended December 31, 2016. The foreign currency gains and losses are associated with SGI, our wholly-owned subsidiary in Australia.

The derivative warrant liability was considered a level 3 fair value financial instrument and was measured at each reporting period until December 31, 2017 at which time the warrants were reclassified to equity due to the expirations of the down-round price protection provision. We recorded a non-cash change in derivative warrant liability gain of ~~$1,009,901~~$431,300 in the ~~three~~six months ended ~~March~~December 31, 2017 compared to a ~~gain~~loss of ~~$694,800~~$168,500 in the ~~three~~six months ended ~~March~~December 31, 2016. The gain represents the decrease in fair value of the outstanding warrants issued in December 2014.

The contingent consideration obligations are considered level 3 fair value financial instruments and will be measured at each reporting period. The $86,688 gain from the non-cash change in contingent consideration obligations expense for the three months ended March 31, 2017 represents the decrease in the estimated fair value of the contingent consideration obligations during that respective period. The $48,963 loss from non-cash change in contingent consideration obligation during the third quarter of fiscal 2016 represents the increase in the estimated fair value of the contingent consideration obligation during that respective period.

~~Loss on equity method investment totaled $95,591~~$0 and ~~$28,916 for the three months ended March 31, 2017 and 2016, respectively. This represents our 50% share of losses incurred by our joint corporation (S&W Semillas S.A.) in Argentina.~~

Non-cash amortization of debt discount expense for the three months ended March 31, 2017 was $150,875 compared to $1,150,412 for the three months ended March 31, 2016. The expense represents the amortization of the debt discount, beneficial conversion feature and debt issuance costs associated with the convertible debentures issued December 31, 2014 and the debt issuance costs associated with our KeyBank working capital facility. The discount is amortized using the effective interest method and the quarterly expense decreases as the net carrying value of the convertible debentures decrease. As of March 1, 2017, the convertible debentures have been fully retired and accordingly, the amortization of debt discount associated with the convertible debentures is complete.

Interest expense during the three months ended March 31, 2017 totaled $300,627 compared to $438,879 for the three months ended March 31, 2016. Interest expense for the third quarter of fiscal 2017 primarily consisted of interest incurred on the note payable issued to DuPont Pioneer as part of the purchase consideration for the DuPont Pioneer acquisition and the working capital credit facilities with KeyBank and NAB. The $138,252 decrease in interest expense in the third quarter of fiscal 2017 is primarily driven by a $246,000 decrease of interest on the convertible debentures as the principal amount of the convertible debentures continues to be redeemed by us and converted by the holders, partially offset by an increase in interest expense attributed to higher levels of working capital resulting in more borrowings on the working capital facilities.

Income tax provision totaled $463,509 for the three months ended March 31, 2017 compared to income tax provision of $5,901 for the three months ended March 31, 2016. Our effective tax rate was 25.9% during the quarter ended March 31, 2017 compared to 1.0% in third quarter of fiscal 2016. The increase in our effective tax rate for the three months ended March 31, 2017 is primarily attributed to the increase in pre-tax book income in combination with the permanent impact of the gain associated with the change in the valuation of our warrants this year compared to the same period in the prior year. The gain associated with the warrant fair value adjustments are not taxable for federal income tax purposes. Our effective tax rate differs from the U.S. federal statutory rate as a result of this nontaxable item and the lower statutory rate of our foreign subsidiary.

~~Nine Months Ended March 31, 2017 Compared to the Nine Months Ended March 31, 2016~~

Revenue for nine months ended March 31, 2017 was $57,487,560 compared to $61,409,948 for the nine months ended March 31, 2016. We recorded sales of approximately $33.9 million from our distribution and production agreements with DuPont Pioneer during the nine months ended March 31, 2017, which was an increase of $3.2 million from the prior period amount of $30.6 million. The increase in revenue to DuPont Pioneer was offset by a decrease in our export business due to delayed shipments into Saudi Arabia. Recent regulatory uncertainty in Saudi Arabia surrounding water use restrictions for large forage producers is causing certain customers in the region to defer purchases and/or reduce inventory carrying levels in the near-term. Based on information currently available to management, we believe that such regulatory uncertainty will be resolved or clarified in the coming months.

Sales to international customers (by destination country) represented 36% and 44% of revenue during the nine months ended March 31, 2017 and 2016, respectively. Domestic revenue accounted for 64% and 56% of our total revenue for the nine months ended March 31, 2017 and 2016, respectively. The increase in domestic revenue is directly attributed to an increase in sales to DuPont Pioneer during fiscal 2017 period. We expect DuPont Pioneer to represent a significant portion of our domestic sales, as well as overall sales, for the foreseeable future.

~~Cost of revenue of $44,520,476 for the nine months ended March 31, 2017 was 77.4% of revenue, while the cost of revenue of $49,890,460 for the nine months ended March 31, 2016 was 81.2% of revenue.~~

Total gross profit margin for the nine months ended March 31, 2017 was 22.6% compared to 18.8% for the nine months ended March 31, 2016. The increase in gross profit margins was primarily due to product sales mix during the current period where we had a higher concentration of sales to DuPont Pioneer which are higher margin sales. Additionally, the product costs of proprietary seed are lower in the current year due to more favorable production contracts and arrangements.

SG&A expense for the nine months ended March 31, 2017 totaled $7,767,530 compared to $7,239,821 for the nine months ended March 31, 2016. The $527,709 increase in SG&A expense versus the comparable period of the prior year was primarily due to bad debt expense of $100,000, an increase in professional fees and personnel and related costs to accommodate the anticipated growth in operations. As a percentage of revenue, SG&A expenses were 13.5% in the current period compared to 11.8% in the nine months ended March 31, 2016.

Research and development expenses for the nine months ended March 31, 2017 totaled $2,204,625 compared to $2,049,332 for the nine months ended March 31, 2016. The increase during the nine months ended March 31, 2017 was primarily driven by additional research and development activities in connection with the recent SVG Acquisition partially offset by reductions in the stevia and alfalfa programs.

Depreciation and amortization expense for the nine months ended March 31, 2017 was $2,475,710 compared to $2,376,101 for the nine months ended March 31, 2016. Included in the amount was amortization expense for intangible assets, which totaled $1,667,932 in the nine months ended March 31, 2017 and $1,673,048 in the nine months ended March 31, 2016. The $99,609 increase in depreciation and amortization expense over the comparable period of the prior year is primarily driven by amortization of intangible assets acquired from SVG Acquisition in May 2016.

We incurred a foreign currency gain of $4,358 for the nine months ended March 31, 2017 compared to a gain of $164,471 for the nine months ended March 31, 2016. The foreign currency gains and losses are associated with SGI, our wholly-owned subsidiary in Australia.

The derivative warrant liability is considered a level 3 fair value financial instrument and is measured at each reporting period. We recorded a non-cash change in derivative warrant liability gain of $841,400 in the nine months ended March 31, 2017 compared to a gain of $2,176,800 in the nine months ended March 31, 2016. The gain represents the decrease in fair value of the outstanding warrants issued in December 2014.

~~The contingent consideration obligations are considered level 3 fair value financial instruments and will be measured at each reporting period. The $77,675 charge~~$164,363 charges to non-cash change in contingent consideration obligations expense for the ~~nine~~six months ended ~~March~~December 31, 2017 and 2016, respectively; represents the increase in the estimated fair value of the contingent consideration obligations during that respective period due to the decrease in the present value discount factor used to estimate the fair value of the contingent consideration obligations. The ~~$1,490 charge~~earn-out payment to ~~non-cash change in contingent consideration obligation during the nine months ended March 31, 2016 represents the decrease~~DuPont Pioneer was finalized in the ~~estimated fair value~~amount of $2,500,000 and this was added to the ~~contingent consideration obligation during that respective period.~~Pioneer Note in October 2017.

Loss on equity method investment totaled ~~$144,841~~$0 and ~~$252,619~~$49,249 for the ~~nine~~six months ended ~~March~~December 31, 2017 and 2016, respectively. This represents our 50% share of losses incurred by our joint corporation (S&W Semillas S.A.) in Argentina. The Company's carrying value in the equity method investee company has been reduced to zero, accordingly, no further losses will be recorded in the Company's consolidated financial statements related to this equity method investment.

Non-cash amortization of debt discount expense for the ~~nine~~six months ended ~~March~~December 31, 2017 was ~~$1,131,994~~$67,099 compared to ~~$3,111,866~~$981,118 for the ~~nine~~six months ended ~~March~~December 31, 2016. The expense in the current period represents the amortization of the debt issuance costs associated with our KeyBank working capital facility and our secured property and equipment notes with Conterra. The expense in the prior year period represents the amortization of the debt discount, beneficial conversion feature and debt issuance costs associated with the convertible debentures issued December 31, ~~2014. The discount is amortized using the effective interest method~~2014 and the ~~quarterly expense will decrease as the net carrying value of the convertible debentures decrease.~~debt issuance costs associated with our KeyBank working capital facility. As of March 1, 2017, the convertible debentures have been fully retired and accordingly, the amortization of debt discount associated with the convertible debentures is complete.

Interest expense during the ~~nine~~six months ended ~~March~~December 31, 2017 totaled ~~$948,211~~$731,623 compared to ~~$1,672,863~~$647,584 for the ~~nine~~six months ended ~~March~~December 31, 2016. Interest expense for the ~~nine~~six months ended ~~March~~December 31, 2017 primarily consisted of interest incurred on the note payable issued to DuPont Pioneer as part of the purchase consideration for the DuPont Pioneer acquisition, the working capital credit facilities with KeyBank and NAB, and the new secured property and equipment loans entered into in November 2017. Interest expense for the six months ended December 31, 2016 primarily consisted of interest incurred on the convertible debentures issued on December 31, 2014, on the note payable issued to DuPont Pioneer as part of the purchase consideration for the DuPont Pioneer acquisition and the working capital credit facilities with KeyBank and NAB. The ~~$724,652 decrease~~$84,039 increase in interest expense for the ~~nine~~six months ended ~~March~~December 31, 2017 is primarily driven by ~~a $850,000 decrease~~$91,363 of interest on the ~~convertible debentures as the principal amount of the convertible debentures continued to be redeemed by us~~secured property and ~~converted by the holders, partially offset with an increase in interest expense attributed to higher levels of working capital resulting in more borrowings on the working capital facilities.~~equipment loans.

Income tax ~~benefit~~expense totaled ~~$533,414~~$200,123 for the ~~nine~~six months ended ~~March~~December 31, 2017 compared to an income tax benefit of ~~$2,773,294~~$996,923 for the ~~nine~~six months ended ~~March~~December 31, 2016. Our effective tax rate expense was ~~42.2% during~~(9.9%) for the ~~nine~~six months ended ~~March~~December 31, 2017 compared to ~~102.0%~~32.6% for the ~~nine~~six months ended ~~March~~December 31, 2016. The decrease in our effective tax rate ~~benefit~~ for the ~~nine~~six months ended ~~March~~December 31, 2017 was primarily attributable to the fact that a valuation allowance against substantially all of our assets was recorded in the fourth quarter of the year ended June 30, 2017. For the six months ended December 31, 2016 we recorded a benefit associated with the tax losses incurred in that period. However, for the six months ended December 31, 2017, we have not recorded a benefit related to our losses due to the valuation allowance. The expense recorded for the six months ended December 31, 2017 is primarily attributed to aadditional deferred tax ~~benefit~~liabilities recorded during the ~~nine months ended March 31, 2016 related to an unrealized foreign currency exchange loss~~year on an inter-company loan to our subsidiary in Australia. We had previously treated the inter-company loan as long-term in investment nature and during the second quarter of fiscal 2016 we determined that the inter-company note would be settled in the foreseeable future. The change in this determination resulted in us recording a tax benefit during the second quarter of fiscal 2016 as the inter-company loan was denominated in Australian dollars and had devalued since the issuance of the loan. The tax benefit related to this foreign exchange loss was recorded in the period that we changed our determination of whether the loan was of long-term investment nature. The benefit was recorded on a pre-tax loss, thus increasing our effective tax rate during the nine months ended March 31, 2016. The reduction in the rate is also attributable to a decrease in the recorded gain associated with the valuation of our warrants in the current period versus the comparable period in the prior year. The gains associated with the warrant fair value adjustments are not taxable for federal income tax purposes. Our effective tax rate differs from the U.S. federal statutory rate as a result of this nontaxable itemindefinite lived intangible assets and the ~~lower statutory rate~~recording of additional tax expense on our ~~foreign subsidiary.~~prior year Australian tax return, which will be filed in fiscal 2018.

Our working capital and working capital requirements fluctuate from quarter to quarter depending on the phase of the growing and sales cycle that falls during a particular quarter. Our need for cash has historically been highest in the second and third fiscal quarters (October through March) because we historically have paid our North American contracted growers progressively, starting in the second fiscal quarter. In fiscal year 2017, we paid our North American growers approximately 50% in October 2016 and the balance was paid in February 2017. This payment cycle to our growers is expected to be similar in fiscal year 2018. SGI, our Australian-based subsidiary, has a production cycle that is counter-cyclical to North America; however, this also puts a greater demand on our working capital and working capital requirements during the second, third and fourth fiscal quarters based on timing of payments to growers in the second through fourth quarters. As a result of the DuPont Pioneer acquisition, which substantially increased our production and therefore our working capital demands, we anticipate our working capital demands to be highest in second and third fiscal quarters due to the payment schedule of our North American grower base.

Historically, due to the concentration of sales to certain distributors, which typically represented a significant percentage of seed sales, our month-to-month and quarter-to-quarter sales and associated cash receipts were highly dependent upon the timing of deliveries to and payments from these distributors, which varied significantly from year to year. The timing of collection of receivables from DuPont Pioneer, which is our largest customer, is defined in the distribution and production agreements with DuPont Pioneer and consists of three installment payments, ~~one in each of~~ the first on September 15th, the second on January 15th, and the third ~~and fourth fiscal quarters.~~payment on February 15th. Our future revenue and cash collections pertaining to the production and distribution agreements with DuPont Pioneer are expected to provide us with greater predictability, as sales to DuPont Pioneer are expected to be primarily concentrated in our second, third and fourth fiscal quarters, and payments will be received in three installments over the September to ~~mid-April~~mid-February time period.

We continuously monitor and evaluate our credit policies with all of our customers based on historical collection experience, current economic and market conditions and a review of the current status of the respective trade accounts receivable balance. Our principal working capital components include cash and cash equivalents, accounts receivable, inventory, prepaid expense and other current assets, accounts payable and our working capital lines of credit.

In addition to funding our business with cash from operations, we have historically relied upon occasional sales of our debt and equity securities and credit facilities from financial institutions, both in the United States and South Australia.

In ~~the prior two fiscal years,~~recent periods, we have consummated the following equity and debt financings:

~~On December 31, 2014, we raised an aggregate of $31,658,400 in gross proceeds in two separate private placements.~~

~~In the first of these two financings, we sold 1,294,000 shares of our common stock at $3.60 per share for gross proceeds of $4,658,400.~~

On the same day, we also sold $27,000,000 aggregate principal amount of 8% Senior Secured Convertible Debentures due November 30, 2017, together with warrants to purchase an aggregate of 2,699,999 shares of our common stock that expire on June 30, 2020. The offering expenses of the debenture and warrant offering totaled approximately $2,355,218, yielding net proceeds of approximately $24,644,782. The net proceeds from these two December 2014 financing transactions were used primarily to fund the cash portion of the purchase price of the DuPont Pioneer Acquisition, with the balance available for working capital and general corporate purposes.

The monthly interest on the debentures was payable cash, in shares of our common stock, provided all of the applicable "equity conditions" defined in the debentures were satisfied, or in any combination of cash and shares, at our option. We have made all monthly redemption payments in cash. Through March 31, 2017, we have reduced the principal amount of the debentures by $7,830,049 through accelerated redemption payments. The principal amount of the debentures has been further reduced by monthly cash redemption payments and optional conversions of the debentures by certain of the holders. A total of 684,321 shares of our common stock, respectively, have been issued upon conversion of the debentures in lieu of payments of principal and accrued interest, totaling an aggregate of $3,168,342. As of March 31, 2017, the Debentures were fully retired and had no outstanding balance.

On December 31, 2014, in connection with the DuPont Pioneer Acquisition, we issued a secured promissory note (the "Pioneer Note") payable by us to DuPont Pioneer in the initial principal amount of $10,000,000 (issued at closing), and a potential earn-out payment (payable as an increase in the principal amount of the Pioneer Note) of up to $5,000,000 based on our sales under the distribution and production agreements entered into in connection with the DuPont Pioneer Acquisition, as well as other sales of products we consummate containing the acquired germplasm in the three-year period following the closing. The earn-out payment of $2,500,000 to DuPont Pioneer was finalized in October 2017 and this amount was added to the Pioneer Note ~~accrues~~in October 2017. The Pioneer Note accrued interest at ~~a rate of~~ 3% per ~~annum, and interest is~~annum. Interest was payable in three annual installments, in arrears, commencing on December 31, 2015. ~~Our~~On December 1, 2017, we repaid the Pioneer Note. The repayment amount included the $2.5 million earn-out payment related to the Pioneer Acquisition that was added to the principal amount of the Pioneer Note in October 2017.

On November 30, 2017, we entered into a secured note financing transaction (the "Loan Transaction") with Conterra Agricultural Capital, LLC ("Conterra") for $12.5 million in gross proceeds. Pursuant to the Loan Transaction, we issued two secured promissory notes (the "Notes") to Conterra as follows:

The Notes and related documents include customary representations and warranties in addition to customary affirmative and negative covenants (including financial covenants), and customary events of default that permit Conterra to accelerate our obligations under the ~~Pioneer Note are secured by certain~~Notes, including, among other things, that a default under one of the ~~assets purchased in~~Notes would constitute a default under the ~~DuPont~~other Note. On December 1, 2017, we used the proceeds from the Loan Transaction to repay the Pioneer ~~Acquisition and are subject to the Intercreditor Agreement. The Pioneer Note matures on December 31, 2017.~~Note.

On November 23, 2015, we completed a private placement transaction with our largest shareholder, MFP Partners, L.P. ("MFP"). In this financing, we sold 1,180,722 shares of our common stock at $4.15 per share for gross proceeds of $4,899,996. The proceeds were used, in part, to partially redeem our outstanding 8% Senior Secured Convertible Debentures issued in December 2014, as well as for working capital and general corporate purposes.49

On February 29, 2016, we completed a rights offering that was made to the holders of common stock, convertible debentures and warrants, with an accompanying contractual participation rights offering made to the holders of the convertible debentures. We issued an aggregate of 1,930,654 shares of common stock at $4.15 per share in the rights offering and an additional 195,028 shares of common stock, also at $4.15 per share, in the accompanying participation rights offering to the debenture holders, for aggregate gross proceeds of $8,821,580. The proceeds were used, in part, to accelerate payments on the convertible debentures and for working capital and general corporate purposes.

On September 22, 2015, we entered into an up to $20,000,000 aggregate principal amount credit and security agreement (the "KeyBank Credit Facility") with KeyBank. On October 4, 2016, we entered into an amendment to the KeyBank Credit Facility effective as of September 30, 2016, temporarily increasing the borrowing limit and certain other credit facility terms as follows: (i) temporarily increasing the borrowing capacity from $20.0 million to (a) up to $25.0 million between October 1, 2016 and November 30, 2016 and (b) up to $30.0 million from February 1, 2017 through March 31, 2017; (ii) temporarily allowing for a $4.0 million over-advance beyond the amounts otherwise available based on the borrowing base calculations, which will be available through February 28, 2017; and (iii) temporarily expanding the borrowing base by reducing the reserves that KeyBank may establish with respect to grower payables to 75% between August 31, 2016 and February 28, 2017. On March 13, 2017, we entered into a Third Amendment Agreement (the "Third Amendment") with respect to the KeyBank Credit Facility. The purpose of the Third Amendment was to provide certain temporary changes to the terms of the KeyBank Credit Facility, including: (i) further extending the temporary period during which we may borrow, repay and reborrow up to $30.0 million in the aggregate under the credit facility until April 21, 2017; and (ii) retroactively and temporarily allowing for over-advances, beyond amounts otherwise available based on the borrowing base calculations under the Credit Facility: (a) of up to $3.5 million during the period from March 8, 2017 through March 10, 2017, (b) of up to $5.0 million during the period from March 11, 2017 through March 17, 2017, (c) of up to $6.0 million during the period from March 18, 2017 through March 24, 2017, (d) of up to $7.0 million during the period from March 25, 2017 through March 31, 2017 and (e) of up to $8.5 million during the period from April 1, 2017 through as late as April 20, 2017.

~~Subject~~ On September 13, 2017, we entered into a Fourth Amendment Agreement (the "Fourth Amendment") with respect to the ~~temporary amended terms provided for~~KeyBank Credit Facility. Pursuant to the Fourth Amendment, we extended the maturity date of the Credit Facility to September 12, 2019 and increased the aggregate principal amount that we may borrow, repay and reborrow, up to $35.0 million in the ~~amendment terms described above, key~~aggregate, subject to a requirement that we maintain a reduced loan balance of (i) not more than $20.0 million for at least 30 consecutive days over the prior twelve months (measured each quarter on a trailing 12 month basis) and (ii) not more than $25.0 million for at least 60 consecutive days over the prior twelve months (measured each quarter on a trailing 12 month basis).

All amounts due and owing, including, but not limited to, accrued and unpaid principal and interest due under the KeyBank Credit Facility, will be payable in full on September ~~21, 2017.~~12, 2019.

The KeyBank Credit Facility generally establishes a borrowing base of up to 85% of eligible domestic accounts receivable ~~(90% if insured)~~and 90% of eligible foreign accounts receivable plus up to the lesser of 65% of the cost eligible inventory or 90% of the net orderly liquidation value, subject to lender reserves.

Loans may be based on a Base Rate or Eurodollar Rate (which is increased by an applicable margin of 2%2.2% per annum) (both as defined in the September 22, 2015 credit and security agreement (the "Credit Agreement")), generally at the Company's option. In the event of a default, at the option of KeyBank, the interest rate on all obligations owing will increase by 3% per annum over the rate otherwise applicable.

Subject to certain exceptions, the KeyBank Credit Facility is secured by a first priority perfected security interest in all our now owned and after acquired tangible and intangible assets and our domestic subsidiaries, which have guaranteed our obligations under the KeyBank Credit Facility. The KeyBank Credit Facility is further secured by a lien on, and a pledge of, 65% of the stock of our wholly-owned subsidiary, S&W Australia Pty Ltd. With respect to its security interest and/or lien, KeyBank has entered into an Intercreditor Agreement with Hudson Bay Fund LP (as agent for the holders of the senior secured debentures issued by us on December 31, 2014) and DuPont Pioneer.

At ~~March~~December 31, 2017, we were in compliance with all KeyBank debt covenants.

In January 2015, NAB and SGI entered into a new business markets - flexible rate loan (the "Keith Building Loan") in the amount of AUD $650,000 (USD ~~$496,827~~$507,130 at ~~March~~December 31, 2017). Since entering into the Keith Building Loan, the limit has been changed on ~~two~~three occasions, with the current limit being AUD ~~$750,000~~$675,000 (USD ~~$573,263~~$526,635 at ~~March~~December 31, 2017), and a separate machinery and equipment facility (the "Keith Machinery and Equipment Facility") has been added ~~of up to~~with the limit being changed on two occasions, the current limit being AUD ~~$1,200,000~~$702,779 (USD ~~$917,220~~$548,308) at ~~March~~December 31, ~~2017).~~2017. At ~~March~~December 31, 2017, the principal balance on the Keith Building Loan was AUD ~~$650,000~~$575,000 (USD ~~$496,828)~~$448,615) with unused availability of AUD $100,000 (USD ~~$76,435)~~$78,021). At ~~March~~December 31, 2017, the principal balance on the Keith Machinery and Equipment Facility was AUD ~~$746,183~~$674,132 (USD ~~$570,345)~~$525,957) with no unused ~~availability of AUD $271,851 (USD $207,789).~~availability. In February 2016, NAB and SGI also entered into a master asset finance facility (the "Master Assets ~~Facility)~~Facility"). At ~~March~~December 31, 2017, the principal balance on the Master Assets Facility was AUD ~~$176,165~~$304,493 (USD ~~$134,652)~~$237,566) with unused availability of AUD ~~$23,835~~$445,507 (USD ~~$18,218)~~$347,585). The Master Asset Facility has various maturity dates through 2021 and have interest rates ranging from ~~4.86%~~4.79% to 5.31%.

~~We are currently in discussions with several financial institutions regarding the refinance of the Pioneer Note and expect to enter~~On July 19, 2017, we entered into a ~~long-term secured promissory note~~Securities Purchase Agreement with certain purchasers, pursuant to ~~fund~~which we sold and issued an aggregate of 2,685,000 shares of our Common Stock at a purchase price of $4.00 per share, for aggregate gross proceeds of $10.74 million.

On October 11, 2017, we entered into a Securities Purchase Agreement with Mark W. Wong, our President and Chief Executive Officer, pursuant to which we sold and issued an aggregate of 75,000 shares of our Common Stock at a purchase price of $3.50 per share, for aggregate gross proceeds of $262,500.

On December 22, 2017, we completed the ~~pay-off~~closing of our rights offering of 3,500,000 shares of our Common Stock. At the ~~Pioneer Note~~closing, we sold and issued an aggregate of 2,594,923 shares of our Common Stock at a subscription price of $3.50 per share (the "Subscription Price"). Pursuant to a backstop commitment with MFP Partners, L.P. ("MFP"), concurrently with the ~~contingent consideration obligation prior to those obligations becoming due. Similarly,~~closing of rights offering, we ~~expect to renew or replace~~sold and issued the remaining 905,077 shares of our ~~KeyBank Credit Facility~~Common Stock not purchased in the ~~normal course~~rights offering to MFP at the subscription price of ~~operations prior to those obligations becoming due. However,~~$3.50 per share. Combined, we ~~cannot provide assurances that additional loans will be available at such times or in amounts needed by us.~~sold and issued an aggregate of 3,500,000 shares of our common stock for aggregate gross proceeds of $12.25 million.

The following table shows a summary of our cash flows for the ~~nine~~six months ended ~~March~~December 31, 2017 and 2016:

		Nine Months Ended				Six Months Ended
		March 31,				December 31,
		2017		2016		2017		2016
Cash flows from operating activities	$	(16,985,511)	$	(3,333,662)	$	(16,669,045)	$	(5,985,615)
Cash flows from investing activities		(1,736,614)		(2,377,320)		(768,845)		(1,382,784)
Cash flows from financing activities		14,979,288		8,434,719		22,072,723		2,664,379
Effect of exchange rate changes on cash		158,996		8,427		74,860		(92,185)
Net (decrease) increase in cash and cash equivalents		(3,583,841)		2,732,164
Net increase (decrease) in cash and cash equivalents						4,709,693		(4,796,205)
Cash and cash equivalents, beginning of period		6,904,500		3,535,458		745,001		6,904,500
Cash and cash equivalents, end of period	$	3,320,659	$	6,267,622	$	5,454,694	$	2,108,295

For the ~~nine~~six months ended ~~March~~December 31, 2017, operating activities used ~~$16,985,511~~$16,669,045 in cash. Net loss plus and minus the adjustments for non-cash items as detailed on the statement of cash flows used $471,624 in cash, and changes in operating assets and liabilities as detailed on the statement of cash flows used $16,197,421 in cash. The decrease in cash from changes in operating assets and liabilities was primarily driven by increases in inventory of $38,850,545 due to timing of the US harvest, partially offset by a corresponding increase in accounts payable of $25,606,471.

For the six months ended December 31, 2016, operating activities used $5,985,615 in cash. Net loss plus and minus the adjustments for non-cash items as detailed on the statement of cash flows provided ~~$3,171,661~~$760,689 in cash, and changes in operating assets and liabilities as detailed on the statement of cash flows used ~~$20,157,172~~$6,746,304 in cash. The decrease in cash from changes in operating assets and liabilities was primarily driven by an increase in inventories of ~~$15,972,829 and a decrease~~$20,836,483 partially offset by an increase in accounts payable (including related parties) of ~~$7,642,270 partially offset by~~$13,560,771 and a decrease in accounts receivable of ~~$4,481,129.~~$1,820,501.

For the nine months ended March 31, 2016, operating activities used $3,333,662 in cash. Net income plus and minus the adjustments for non-cash items as detailed on the statement of cash flows provided $1,090,408 in cash and changes in operating assets and liabilities as detailed on the statement of cash flows used $4,424,070 in cash. The decrease in cash from changes in operating assets and liabilities was primarily driven by increases in inventory of $16,946,534 attributed to the 2016 Australian harvest, partially offset by decreases in accounts receivable of $13,498,542.

Investing activities during the six months ended December 31, 2017 used $768,845 in cash. These activities consisted primarily of additions to a build out of a new research and development facility in Nampa, Idaho.

Investing activities during the ~~nine~~six months ended ~~March~~December 31, ~~2017~~2016 used ~~$1,736,614~~$1,382,784 in cash. These activities consisted primarily of additions to a build out of a new research and development facility in Nampa, Idaho and investment in internal use software.

Investing activities during the nine months ended March 31, 2016 used $2,377,320 in cash. These activities consisted of additions to property, plant and equipment, primarily for the build out of the new packaging and distribution facility in Keith, Australia and a build out of a new research and development facility in Nampa, Idaho. In addition, we invested $439,038 in our 50% owned joint corporation, S&W Semillas S.A.53

Financing activities during the ~~nine~~six months ended ~~March~~December 31, 2017 provided ~~$14,979,288~~$22,072,723 in cash. We completed two separate private placements of common stock during the six months ended December 31, 2017 which raised net proceeds of $10.7 million in cash. In December 2017, we also completed the closing of our rights offering and backstop commitment with MFP. Pursuant to the rights offering and backstop commitment with MFP, we sold and issued an aggregate of 3,500,000 shares of our common stock in December 2017 for aggregate net proceeds of $11.8 million. On November 30, 2017, we entered into a secured note financing transaction for $12.5 million in gross proceeds. The proceeds from the secured note financing were used to repay the Pioneer Note. The repayment amount included the $2.5 million earn-out payment related to the Pioneer Acquisition that was added to the principal amount of the Pioneer Note in October 2017.

Financing activities during the six months ended December 31, 2016 provided $2,664,379 in cash. We had net borrowings of ~~$19.3~~$5.6 million on our lines of credit and made ~~$4.7~~$3.4 million of redemptions on our convertible debentures. We also generated ~~$0.6 million~~$602,083 in net proceeds from the exercise of stock options during the ~~nine~~six months ended ~~March~~December 31, ~~2017.~~2016.

Financing activities during the nine months ended March 31, 2016 provided $8,434,719 in cash. In February 2016, we completed a rights offering of common stock offered to holders of common stock, convertible debentures and warrants and an accompanying contractual participation rights offering made to the holders of the convertible debentures. We also completed a private placement of common stock in November 2015. These equity financings collectively raised net proceeds of $13.3 million in cash. We also had net borrowings of $7.8 million on our lines of credit and made $11.3 million of redemptions on our convertible debentures as well as $2.0 million of other debt payments.

We do not believe that inflation has had a material effect on our business, financial condition or results of operations, including our revenue and income from continuing operations. However, if our costs were to become subject to significant inflationary pressures, we may not be able to fully offset such higher costs through price increases. Our inability or failure to do so could harm our business, financial condition and results of operations.

We did not have any off-balance sheet arrangements during the three and ~~nine~~six months ended ~~March~~December 31, 2017.

Our future liquidity and capital requirements will be influenced by numerous factors, including:

The accounting policies and the use of accounting estimates are set forth in the footnotes to our consolidated financial statements.

In preparing our financial statements, we must select and apply various accounting policies. Our most significant policies are described in Note 2 - Summary of Significant Accounting Policies of the footnotes to the consolidated financial statements. In order to apply our accounting policies, we often need to make estimates based on judgments about future events. In making such estimates, we rely on historical experience, market and other conditions, and on assumptions that we believe to be reasonable. However, the estimation process is by its nature uncertain given that estimates depend on events over which we may not have control. If market and other conditions change from those that we anticipate, our results of operations, financial condition and changes in financial condition may be materially affected. In addition, if our assumptions change, we may need to revise our estimates, or to take other corrective actions, either of which may also have a material effect on our results of operations, financial condition or changes in financial condition. Members of our senior management have discussed the development and selection of our critical accounting estimates, and our disclosure regarding them, with the audit committee of our board of directors, and do so on a regular basis.

We believe that the following estimates have a higher degree of inherent uncertainty and require our most significant judgments. In addition, had we used estimates different from any of these, our results of operations, financial condition or changes in financial condition for the current period could have been materially different from those presented.

All amortizable intangible assets are assessed for impairment whenever events indicate a possible loss. Such an assessment involves estimating undiscounted cash flows over the remaining useful life of the intangible. If the review indicates that undiscounted cash flows are less than the recorded value of the intangible asset, the carrying amount of the intangible is reduced by the estimated cash-flow shortfall on a discounted basis, and a corresponding loss is charged to the consolidated statement of operations. Significant changes in key assumptions about the business, market conditions and prospects for which the intangible asset is currently utilized or expected to be utilized could result in an impairment charge.

We account for stock-based compensation in accordance with FASB Accounting Standards Codification Topic 718 Stock Compensation, which establishes accounting for equity instruments exchanged for employee services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee's requisite service period (generally the vesting period of the equity grant).

We account for equity instruments, including stock options issued to non-employees, in accordance with authoritative guidance for equity-based payments to non-employees (FASB ASC 505-50). Stock options issued to non-employees are accounted for at their estimated fair value. The fair value of options granted to non-employees is re-measured as they vest.

We utilize the Black-Scholes-Merton option pricing model to estimate the fair value of options granted under share-based compensation plans. The Black-Scholes-Merton model requires us to estimate a variety of factors including, but not limited to, the expected term of the award, stock price volatility, dividend rate, risk-free interest rate. The input factors to use in the valuation model are based on subjective future expectations combined with management judgment. The expected term used represents the weighted-average period that the stock options are expected to be outstanding. We have used the historical volatility for our stock for the expected volatility assumption required in the model, as it is more representative of future stock price trends. We use a risk-free interest rate that is based on the implied yield available on U.S. Treasury issued with an equivalent remaining term at the time of grant. We have not paid dividends in the past and currently do not plan to pay any dividends in the foreseeable future, and as such, dividend yield is assumed to be zero for the purposes of valuing the stock options granted. We evaluate the assumptions used to value stock awards on a quarterly basis. If factors change, and we employ different assumptions, share-based compensation expense may differ significantly from what we have recorded in the past. When there are any modifications or cancellations of the underlying unvested securities, we may be required to accelerate, increase or cancel any remaining unearned share-based compensation expense. To the extent that we grant additional equity securities to employees, our share-based compensation expense will be increased by the additional unearned compensation resulting from those additional grants.

We regularly assess the likelihood that deferred tax assets will be recovered from future taxable income. To the extent management believes that it is more likely than not that a deferred tax asset will not be realized, a valuation allowance is established. When a valuation allowance is established or increased, an income tax charge is included in the consolidated financial statements and net deferred tax assets are adjusted accordingly. Changes in tax laws, statutory tax rates and estimates of our future taxable income levels could result in actual realization of the deferred tax assets being materially different from the amounts provided for in the consolidated financial statements. If the actual recovery amount of the deferred tax asset is less than anticipated, we would be required to write-off the remaining deferred tax asset and increase the tax provision, resulting in a reduction of earnings and stockholders' equity.

All inventories are accounted for on a lower of cost or market basis. Inventories consist of raw materials and finished goods as well as in the ground crop inventories. Depending on market conditions, the actual amount received on sale could differ from our estimated value of inventory. In order to determine the value of inventory at the balance sheet date, we evaluate a number of factors to determine the adequacy of provisions for inventory. The factors include the age of inventory, the amount of inventory held by type, future demand for products and the expected future selling price we expect to realize by selling the inventory. Our estimates are judgmental in nature and are made at a point in time, using available information, expected business plans and expected market conditions. We perform a review of our inventory by product line on a quarterly basis.

Our subsidiary, SGI, does not fix the final price for seed payable to its growers until the completion of a given year's sales cycle pursuant to its standard contract production agreement. We record an estimated unit price accordingly, inventory, cost of revenue and gross profits are based upon management's best estimate of the final purchase price to our SGI growers. To the extent the estimated purchase price varies from the final purchase price for seed, the adjustment to actual could materially impact the results in the period when the difference between estimates and actuals are identified. If the actual purchase price is in excess of our estimated purchase price, this would negatively impact our financial results including a reduction in gross profits and earnings.

We regularly assess the collectability of receivables and provide an allowance for doubtful trade receivables equal to the estimated uncollectible amounts. That estimate is based on historical collection experience, current economic and market conditions and a review of the current status of each customer's trade accounts receivable. Our estimates are judgmental in nature and are made at a point in time. Management believes the allowance for doubtful accounts is appropriate to cover anticipated losses in our accounts receivable under current conditions; however, unexpected, significant deterioration in any of the factors mentioned above or in general economic conditions could materially change these expectations.

We are a smaller reporting company and therefore, we are not required to provide information required by this item of Form 10-Q.

Our management, with the participation of our ~~Chief~~Principal Executive Officer and our ~~Chief~~Principal Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of ~~March~~December 31, ~~2017.~~2017 (the "Evaluation Date"). The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of ~~March~~December 31, 2017, our ~~Chief~~Principal Executive Officer and ~~Chief~~Principal Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

There have been no significant changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and ~~15d-15(f)~~15d- 15(f) under the Exchange Act) or in other factors that occurred during the period of our evaluation ~~or subsequent to the date we carried out our evaluation which~~that have ~~materially~~significantly affected, or are reasonably likely to ~~materially~~significantly affect, our internal control over financial reporting. The design of any system of controls and procedures is based in part upon certain assumptions about the likelihood of future events. There can be no assurance that any system of controls and procedures will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.

Our business and results of operations are subject to a number of risks and uncertainties. A description of the risk factors associated with our business is included under the heading "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended June 30, 2016, which was filed with the SEC on September 15, 2016. The description below includes material changes to the risk factors affecting our business that were previously disclosed in our Annual Report and supersedes the description of the relevant risk factor in our Annual Report. Other than the items discussed below,While there have been no material changes to the risk factors previously disclosed under the heading "Risk Factors" in our Annual Report, ~~since such filing.~~

which was filed with the SEC on September 20, 2017, you should carefully consider the risk factors described therein. The ~~future demand for~~occurrence of any of the risks described in our ~~non-dormant alfalfa seed varieties~~Annual Report or herein could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in ~~Saudi Arabia is uncertain.~~

~~Recent regulatory uncertainty~~forward-looking statements we have made in ~~Saudi Arabia surrounding water use restrictions for large forage producers is causing buyers in the country~~this Quarterly Report on Form 10-Q and those we may make from time to reduce alfalfa seed inventory levels in the near-term. Historically, sales to customers in Saudi Arabia have represented a significant portion of our revenue, and one Saudi Arabia based customer still ranks among our largest two customers. Given the regulatory uncertainty, the outlook for demand for our non-dormant varieties in Saudi Arabia over the next two to four years is uncertain. If buyers in Saudi Arabia continue to reduce alfalfa seed inventory levels in the near-term, our revenue over the next three to twelve months could be negatively impacted. If such regulatory uncertainty perseveres, or if such regulations are clarified or resolved in a manner that unfavorably impacts the water usage rights of large forage producers in Saudi Arabia, we could experience a significant decrease in demand from our customers in Saudi Arabia. Any such decrease in demand could result in a material decline in revenue and earnings in the absence of growth in other regions and other products.time.

~~See the Exhibit Index immediately following the signature page of this Quarterly Report, which is incorporated herein by reference, for the exhibits filed as part of this Quarterly Report.~~

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on the 10th day of May, 2017.

~~S&W SEED COMPANY~~

~~By:~~ ~~/s/ Matthew K. Szot~~

~~Matthew K. Szot~~

          ~~Executive Vice President of Finance and Administration and Chief Financial Officer~~
           ~~(duly authorized on behalf of the registrant and~~
           ~~principal financial and accounting officer)~~

S&W SEED COMPANY

By: /s/ Matthew K. Szot

Matthew K. Szot

          Executive Vice President of Finance and Administration and Chief Financial Officer
           (duly authorized on behalf of the registrant and
           principal financial and accounting officer)

PART I. FINANCIAL INFORMATION	Page No.

Item 1. Financial Statements (Unaudited):

Consolidated Balance Sheets at ~~March~~December 31, 2017 and June 30, ~~2016~~2017	4

Consolidated Statements of Operations for the Three and ~~Nine~~Six Months Ended ~~March~~December 31, 2017 and 2016	5

Consolidated Statements of Comprehensive Income (Loss) for the Three and ~~Nine~~Six Months Ended ~~March~~December 31, 2017 and 2016	6

Consolidated Statements of Stockholders' Equity for the ~~Nine~~Six Months Ended ~~March~~December 31, 2017 and 2016	7

Consolidated Statements of Cash Flows for the ~~Nine~~Six Months Ended ~~March~~December 31, 2017 and 2016	8

Notes to Consolidated Financial Statements	9

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	3435

Item 3. Quantitative and Qualitative Disclosures About Market Risk	5357

Item 4. Controls and Procedures	5457

PART II. OTHER INFORMATION

Item 1. Legal Proceedings	5458

Item 1A. Risk Factors	5458

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	5558

Item 3. Defaults Upon Senior Securities	5558

Item 4. Mine Safety Disclosures	5558

Item 5. Other Information	5558

Item 6. Exhibits	5559

		~~May 26, 2016~~
~~Accounts receivable~~	$	~~37,888~~
~~Inventory~~		~~150,000~~
~~Liabilities assumed~~		~~(16,901)~~
~~Property, plant and equipment~~		~~45,273~~
~~Technology/IP - germplasm~~		~~479,000~~
~~Technology/IP - seed varieties~~		~~57,000~~
~~Customer relationships~~		~~462,000~~
~~Trade name~~		~~45,000~~
~~Non-compete agreements~~		~~30,000~~
~~Goodwill~~		~~796,064~~
~~Total acquisition cost allocated~~	$	~~2,085,324~~

		~~May 26, 2016~~
~~Cash~~	$	~~1,000,000~~
~~Restricted stock consideration~~		~~950,000~~
~~Contingent earn-out~~		~~135,324~~
	$	~~2,085,324~~

		~~March 31, 2017~~		~~June 30, 2016~~
~~Current portion of convertible debt, net~~
~~Senior secured convertible notes payable~~	$	-	$	~~7,849,754~~
~~Debt discount~~		-		~~(1,009,146)~~
~~Total convertible debt, net~~	$	-	$	~~6,840,608~~

Exhibit No.		Description
2.1		Fourth Amendment to Asset Purchase and Sale Agreement between the Registrant and Pioneer Hi-Bred International, Inc., dated December 4, 2017.
3.1(1)		Registrant's Articles of Incorporation.
3.2(2)		Registrant's Second Amended and Restated Bylaws.
4.1		Reference is made to Exhibits 3.1 and 3.2.
4.2(3)		Form of Common Stock Certificate.
4.3(4)		Form of Common Stock Purchase ~~Warrant issued to Rodman & Renshaw, LLC~~Warrant.
~~4.4(5)~~10.1(5)		~~Form of Common Stock Purchase Warrant~~Investment Agreement, by and between the Registrant and MFP Partners, L.P., dated October 3, 2017.
~~4.5(6)~~10.2(6)		~~Form~~Securities Purchase Agreement by and between the Registrant and Mark W. Wong, dated October 11, 2017.
10.3(6)		Registration Rights Agreement by and between the Registrant and Mark W. Wong, dated October 11, 2017.
10.5		Secured Promissory Notes issued by the Registrant in favor of ~~8% Senior Secured Convertible Debentures~~Conterra Agricultural Capital, LLC, dated November 30, 2017 and related documents.
10.6		Third Amendment to Contract Alfalfa Production Services Agreement between the Registrant and Pioneer Hi-Bred International, Inc., dated December 21, 2017.
10.7		First Amendment to Research Agreement between the Registrant and Pioneer Hi-Bred International, Inc., dated December 21, 2017.
10.8(7)		Registration Rights Agreement by and between the Registrant and MFP Partners, L.P., dated December 22, 2017.
31.1		Certification of Chief Executive Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2		Certification of Chief Financial Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

	Estimated Useful Life (Years)		Estimated Fair Value
Technology/IP - germplasm	25	$	479,000
Technology/IP - seed varieties	15		57,000
Customer relationships	10		462,000
Trade name	10		45,000
Non-compete agreements	5		30,000
Total identifiable intangible assets		$	1,073,000

32.1		Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2		Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document